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ABSTRACT OF CAPSTONE 
 
 
 
MALIGNANT MELANOMA IN KENTUCKY: AN ANALYSIS OF 
INDIVIDUAL AND SOCIAL FACTORS ON DISEASE STAGE AND 
TREATMENT 
 
 
Introduction: In 2016 there will be an estimated 76,380 new cases of malignant 
melanoma and 10,130 deaths in the United States (US). 1 Malignant melanoma 
incidence is increasing faster than any other preventable cancer in the US with 
an expected 112,000 new cases a year by 2030. 2,3 This capstone attempts to 
quantify the association of individual and social factors on melanoma late-stage 
diagnosis and non-adherence to surgical treatment guidelines for early-stage 
lesions in Kentucky.   
Methods: The analysis combines three datasets: individual level data from the 
Kentucky Cancer Registry, census tract level data from the US Census and 
county level physician licensure data from the Kentucky Department of Public 
Health. Descriptive statistics, univariate and multivariate logistic regression 
analyses were completed.  
Results: The first paper hypothesized that late-stage diagnosis is associated 
with an increase in poverty level, decrease in education level and decrease in 
physician density.  An association between these variables of interest were not 
found, rather, this study supports previous research that there is decreased odds 
of late-stage diagnosis if female, married and carry private insurance.  65,123,125 
The second paper hypothesized that non-standard treatment more frequently 
occurs in rural and Appalachian regions and geographic areas with lower 
physician density and lower socioeconomic status as indicated by an increase in 
poverty level and decrease in education level. An association between non-
standard treatment and Appalachian geography, poverty level and physician 
density was found. Non-standard treatment was provided to 40% of early-stage 
cases and this rate is rising.  
Conclusions: Kentucky is a rural state with high poverty, lower than average 
education levels and low physician density but it appears that these factors have 
not impacted melanoma stage of diagnosis. Instead, policy implementation 
should focus on the need to increase patient access to melanoma care and 
educating clinicians to halt the trend of increasing non-standard melanoma 
surgical treatment for early-stage lesions in the Commonwealth.  
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status; Appalachian; treatment guidelines 
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CHAPTER I 
 
 
Introduction 
 
In 2016 there will be an estimated 76,380 new cases of malignant 
melanoma and 10,130 deaths in the United States (US). 1 Malignant melanoma 
(here forward referred to as melanoma) incidence is increasing faster than any 
other preventable cancer in the US with an expected 112,000 new cases a year 
by 2030. 2,3 This is a public health concern because as rates steadily rise there is 
no universal screening recommendation. 4,5  
Melanoma is an intriguing disease; unlike other forms of cancer the 
incidence occurs in a positive social gradient, where those with a higher 
socioeconomic status (SES) have the highest incidence. Meanwhile those with 
low SES have higher rates of late-stage disease and higher mortality rates.6 
These findings have led to an interest in further delineating the characteristics of 
those people who have melanoma by disease stage and how their disease is 
treated.  
As more than 90% of all US melanoma lesions develop in non-Hispanic 
whites, Kentucky makes an interesting place to study this disease because 89% 
of the population is white with an above average poverty rate of 19%. 7,8 
Kentucky also has a higher rate of melanoma compared to the US with a survey 
noting that some counties such as Russell and Warren ranking among the 
highest in the country. 9 Additionally, as the increasing mortality rate from 
melanoma leveled off in the US in the late 1980s the level has continued to rise 
in Kentucky. 10 There may be several factors, individual and/or social, in 
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Kentucky that are impacting melanoma incidence and mortality as the 
Commonwealth has a higher proportion of the population which is generally 
impoverished, rural, and medically underserved compared to other states. 8,11,12  
Studies have shown that melanoma disease stage and treatment is 
influenced by both individual and social factors. These factors include age, 
gender, race, ultraviolet radiation (UVR) exposure, SES, marital status, 
geographic location, tumor histology, tumor location, insurance status, access to 
health care, and prevention efforts of sun-protective behaviors, risk awareness 
and early detection efforts. 7,13-25 Additionally, the stage of diagnosis and 
receiving appropriate treatment for that stage directly impacts melanoma 
survival. 26,27 Despite specific treatment guidelines from the National 
Comprehensive Cancer Network (NCCN) the evidence suggests that these 
melanoma surgical guidelines are not followed half of the time. 28   
 
Purpose of the study 
The purpose of this capstone is to understand the variables leading to 
late-stage disease diagnosis and the high mortality rate in Kentucky. This will be 
done through a logistic regression analysis of individual and social factors on 
melanoma stage of diagnosis and surgical treatment provided.  
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Figure 1.1, Flow Diagram of Malignant Melanoma and Individual and 
Social Factors with Possible Association with Disease Stage and Treatment 
 
 
 
This capstone will include two papers, which will quantify the association 
of individual and social factors on melanoma late-stage diagnosis and non-
adherence to surgical treatment guidelines for early-stage lesions in Kentucky.  
Refer to figure 1.1. The hope is that by determining the factors that are attributing 
to late-stage diagnosis and surgical treatment guideline non-adherence for early-
stage lesions that an area for direct public health intervention will be uncovered.  
Paper one will describe the incidence and mortality rates of malignant melanoma 
in white non-Hispanic Kentuckians from 1995 to 2013. Then the association of 
individual and social variables (age, gender, marital status, year of diagnosis, 
anatomical site of lesion, health insurance status, urban/rural geography, 
Appalachian/non-Appalachian geography, poverty level, education level and 
Melanoma
•Disease stage
•Surgical TreatmentIndividual Factors
•Age
•Gender
•Marital Status
•Year of diagnosis
•Anatomic site
• Insurance status
Social Factors
•Poverty
•Education
•Urban vs Rural 
geography
•Appalachian 
geography
•Physician 
population ratio
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physician population ratio) on incidence rates of all cases, early-stage and late-
stage melanoma, in white non-Hispanic Kentuckians from 1995 to 2013 will be 
quantified. 
Paper two will report the percentage of cases with early-stage disease that 
did not adhere to the standard of care treatment, defined as clear margins, in 
white non-Hispanic Kentuckians from 1995 to 2013. Then the association of 
individual and social variables  (age, gender, marital status, year of diagnosis, 
anatomical site of lesion, health insurance status, urban/rural geography, 
Appalachian/non-Appalachian geography, poverty level, education level and 
physician population ratio) on the treatment provided to early-stage melanoma 
cases in white non-Hispanic Kentuckians from 1995 to 2013 will be quantified.   
The high poverty rate combined with the high incidence and mortality rates of 
melanoma in Kentucky make this an interesting study.  This study is relevant due 
to the continued rise in melanoma incidence with no clear public health solution.  
While most studies have looked at melanoma by analyzing a few variables, this 
study attempts to analyze both individual and social determinants. The analysis 
combines three datasets: individual level data from the Kentucky Cancer Registry 
(KCR), census tract level data from the US Census and county level physician 
licensure data from the Kentucky Department of Public Health.  
 
Limitations, Delimitations, Innovations 
There are some important limitations to this proposal. First, there is the 
utilization of community level variables for SES as individual level variables are 
not available. The contextual variables of poverty and education for SES will be 
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utilized to understand the impact of the community on melanoma stage of 
diagnosis and treatment. The use of aggregate measures for SES has been 
validated but both poverty and education contextual variables represent 
community level data and not individual level data. 29-31 Also, physician 
population ratio is used as an aggregate to evaluate health care access but we 
cannot know the amount of services used by the patients individually. This data 
is cross sectional from 2006 and may not fully represent the small variation in the 
physician workforce from 1995 to 2013. Additionally, this data did not account for 
other medical providers including physician assistants and nurse practitioners. To 
provide more accurate individual representation of the community level variables 
of poverty, education and physician density this data was provided at the county 
level in a state with 120 counties. Future research may better capture community 
level characteristics by analysis with larger geographic regions.  Although this 
study analyzes multiple variables, melanoma subtypes are not included so the 
effect of this variable cannot be investigated in this study. Lastly, this study is 
restricted to melanoma cases in Kentucky and may not be representative of other 
forms of skin cancer or other regions of the country.  
Several delimitations have been placed on this study. As the majority of the 
population in Kentucky is white non-Hispanics this will be the population studied. 
Therefore, the effect of race on both disease stage and treatment cannot be 
determined. Also, due to the low mortality rate the variables impacting survival 
will not be studied. Lastly, with the changes in the standard of care for surgical 
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and chemotherapy treatment during the time period of study, this study will only 
analyze surgical treatment via clear surgical margins of localized disease.  
This study also offers several innovations.  This analysis will be the first to 
provide insight into the high melanoma incidence and mortality rate in Kentucky.  
The study population offers an opportunity to study previously investigated 
factors in a rural, impoverished and lowered educated state. This analysis will 
also be the first to provide a regression analysis looking at individual and social 
determinants of non-adherence to melanoma surgical treatment guidelines in 
Kentucky. Additionally, this study design provides a novel methodology by 
evaluating if the melanoma NCCN guidelines for surgical treatment were followed 
in a mostly rural and Appalachian population.  This evaluation of individual and 
social determinants will lend needed insight into the complexity of providing the 
standard of care surgical treatment for melanoma. The purpose of this capstone 
is to help guide future public health interventions for melanoma in Kentucky.  
This capstone will be divided by chapters and include two separate papers 
with background, methods, results and discussion sections that examine two 
distinct facets of melanoma as described above. Chapter two will begin with a 
comprehensive literature review of melanoma pathophysiology, staging, 
treatment, incidence, prevalence, mortality, risk factors, prevention and screening 
recommendations.  This will be followed by a detailed account of the variables 
that have been found to influence disease stage and surgical treatment.  
Following the literature review, chapter three will contain paper one which is an 
analysis of the individual and social variables associated with late-stage 
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melanoma diagnosis in the Commonwealth.  Chapter four will then include paper 
two which is an analysis of the individual and social variables associated with 
non-adherence to surgical treatment provided for early-stage melanoma. Lastly, 
chapter five will summarize the capstone by providing further conclusions and 
recommendations.  
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CHAPTER 2 
 
Literature review 
 This chapter is a literature review of melanoma pathophysiology, staging, 
treatment, incidence, prevalence, mortality, risk factors, prevention and screening 
recommendations. This will be followed by a comprehensive review of the 
literature on variables that have been shown to effect melanoma stage of 
diagnosis and adherence to surgical treatment guidelines.  This review 
comprises the most recent and relevant research regarding melanoma.  The 
works cited were gathered from presentations, books and peer reviewed 
journals.  The databases used were PubMed, Scopus, Embase, Tripp, 
UpToDate, and MedlinePlus. Key word searches included melanoma, disease 
stage, treatment, treatment guidelines, incidence, mortality, socioeconomic 
status, poverty, education, Kentucky, and Appalachian region.  Further review of 
the literature encompassed reviewing the US and European treatment 
guidelines, referencing bibliographies of seminal articles as well as those 
recommended by experts and colleagues.   
Pathophysiology, Staging and Treatment 
 
The largest human organ is the skin and it is the first line of protection for 
the human body. 32 The epidermis is the thin most superior layer of the skin and 
keratinocytes that provide a physicochemical barrier are the most abundant cell 
within the epidermis. Melanocytes are the only source of pigment in the skin and 
are found in both the epidermis and dermis. 33 Melanocytes can form malignant 
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melanoma or benign skin lesions such as moles or spitz nevus. 23,34   
Keratinocytes contain most of the melanin in the skin and act as a natural 
sunscreen to protect the skin against ultraviolet radiation (UVR). 33 UVR 
sensitivity and skin complexion are determined by the amount and type of 
epidermal melanin.  There are two types of melanin: eumelanin-- a dark pigment 
expressed profusely in the skin of heavily pigmented people that is protective and 
pheomelanin-- a light-colored pigment that is seen in fair-skinned people. This 
difference in melanin explains why fair-skinned people experience more UVR 
damage. 33   
Cancer is a dysregulation of cell division in which the cell continues to 
divide without limitations.  Cancer cells also reproduce more rapidly and in a 
disorganized fashion. 35 The common types of skin cancer are squamous cell 
carcinoma, basal cell carcinoma and melanoma.  Melanoma is considered a 
pigmented skin cancer that is significantly more aggressive and deadly than the 
other forms of skin cancer.32 The complexity of melanoma is not fully understood 
yet it is now widely accepted that melanoma development occurs from interplay 
of genetics and exposure to UVR radiation. 36  
Continued research into UVR exposure has led to the clinical description 
of subtypes cutaneous melanoma: non-chronic sun damage and chronic sun-
induced damage. 37 The non-chronic sun damaged lesions are noted to have a 
high proportion of BRAF mutations. 38 The worldwide study of families with high 
rates of melanoma has found genetic germline mutations in CDKN2A and 
CDK4.39,40  Although important information, it is unlikely that these genetic 
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findings play a large role in population-based melanoma. 40 Whereas, recent 
findings through epigenomics, the Cancer Genome Atlas project and research 
into stem cells has helped to explain the role of pathways such as mitogen-
activated protein, BRAF mutation, VEGFR1, CD133 and CD34. 41 As research 
works towards a full understanding of melanoma these findings have led to the 
development of promising molecular targeted therapies. 
Melanoma can be found on any area of the body that has melanocytes 
which includes the skin, meninges, mucous membranes and eyes. 32 Melanoma 
is distinctive in that it can arise anywhere on the body including the palms or 
soles of the feet. 42 Also unique, melanocytes form lesions that are dark in 
appearance yet not all melanoma lesions are dark. 23,42 
Melanoma presents as one of four subtypes: superficial spreading, 
nodular, lentigo maligna and acral lentiginous. 32 Superficial spreading is the 
most common variant comprising 70% of all lesions and has a good prognosis. 
These lesions are dark black to red and found on the back or in women on the 
lower legs. Nodular lesions are the subtype with the worst prognosis and 
comprise 15-30% of all lesions. Nodular lesions are seen anywhere on the body 
with variation between black to pink lesions and have the shortest growth cycle of 
any subtype. Lentigo maligna lesions comprise 10-15% of all lesions and have a 
good prognosis. They appear tan brown and present on people over 70 years of 
age on the sun-exposed surfaces of the skin.  Acral lentiginous lesions have a 
poor prognosis and are the least common subtype comprising less than 5% of all 
lesions. These lesions are a brown to blue color and appear on the soles, palms, 
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nail beds and mucous membranes. 32,43-45 Each type of lesion has distinct 
characteristics and growth durations yet the histopathology is not considered a 
distinct prognostic indicator. 32 Instead the location of the lesion affects the 
outcome with those arising on the arm doing better than those on the leg, which 
do better than those on the head and neck with finally those lesions on the trunk 
have the worse prognosis. 46 This wide range of presentations can make both 
screening and diagnosis difficult. 23,34  
In 1970 Breslow noted that staging based on tumor thickness was the best 
prognostic indicator for survival of melanoma and this is still true today. 26 The 
deeper or thicker the lesion with spread into the dermis and subcutaneous layers 
of the skin the more advanced the stage of disease. 47 Before staging a 
melanoma lesion it must be classified into the tumor node metastasis (TNM) 
classification system developed by the American Joint Committee on Cancer 
(AJCC). 48 See Table 2.1. Important indicators for TNM classification and thus 
survival include lesion thickness, mitosis, ulceration, lymph nodes involvement 
with micrometastasis or macrometastasis, number of lymph nodes involved and if 
metastasis is present, the site of metastasis and lactate dehydrogenase (LDH) 
level. 17,18,47 The TNM classification underwent an important revision in 2009 with 
the removal of the Clark level of invasion and adding the mitotic rate. 18 The 
mitotic rate, or the proliferation of the melanoma lesion defined by number of 
mitosis/mm2, was identified as a powerful independent predictor of survival.  
Mitotic rate is second only to Breslow tumor thickness as a predictor for survival 
in localized melanoma. 17,18  
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Table 2.1 
TNM Classification for Melanoma 48 
 
T classification Lesion thickness (mm) Ulceration Status/Mitosis 
TX Primary tumor cannot be assessed NA 
T0 No evidence of primary tumor NA 
Tis Melanoma in situ NA 
T1 <1.0  a. Without ulceration and 
mitosis < 1mm2 
b. With ulceration and 
mitosis < 1 mm2 
T2 1.01-2.0 a. Without ulceration 
b. With ulceration 
T3 2.01-4.0 a. Without ulceration 
b. With ulceration 
T4 >4.0 a. Without ulceration 
b. With ulceration 
N classification Number of lymph nodes (LN) Nodal Metastatic Mass 
NX Regional LN cannot be assessed NA 
N0 0 NA 
N1 1 a. Micrometastasis* 
b. Macrometastasis** 
N2 2-3 a. Micrometastasis* 
b. Macrometastasis** 
c. In transit 
metastases/satellites 
without metastatic nodes 
N3 4+ metastatic nodes, or matted nodes, 
or in transit metastases/satellites with 
metastatic nodes  
 
M classification Site Serum LDH 
M0 No detectable evidence NA 
M1a Distant skin, subcutaneous, distant LN Normal 
M1b Lung Normal 
M1c All other visceral sites 
Any distant metastasis 
Normal 
Elevated 
NA: not applicable; LDH: lactate dehydrogenase 
*Micrometastases are diagnosed after sentinel lymph node biopsy 
**Macrometastases are defined as clinically detectable nodal metastases confirmed 
pathologically  
 
 
 
 
 13 
Following this classification a melanoma lesion is further sorted into stage 
I through IV by the AJCC cancer-staging manual. 48 Refer to Table 2.2. For 
research purposes the stages are commonly divided into early and late-stages 
with early-stage including localized disease, which is defined as stage, I or II.  
Late-stage includes regional disease defined as stage III and metastatic disease 
defined as stage IV. 21,47,49 Less than 5% of patients are diagnosed with 
metastatic disease while approximately 10% present with regional disease and 
an estimated 85% present with localized disease. 47 This meticulous staging 
process allows for an accurate diagnosis, treatment plan and prognosis.  
 
 
Table 2.2 
Melanoma Staging 48  
 
Stage Tumor Node Metastasis 
Stage 0 Tis N0 M0 
Stage IA T1a N0 M0 
Stage IB T1b N0 M0 
 T2a N0 M0 
Stage IIA T2b N0 M0 
 T3a N0 M0 
Stage IIB T3b N0 M0 
 T4a N0 M0 
Stage IIC T4b N0 M0 
Stage IIIA T (1-4) a N1a M0 
 T (1-4) a N2a M0 
Stage IIIB T (1-4) b N1a M0 
 T (1-4) b N2a M0 
 T (1-4) a N1b M0 
 T (1-4) a N2b M0 
 T (1-4) a N2c M0 
Stage IIIC T (1-4) b N1b M0 
 T (1-4) b N2b M0 
 T (1-4) b N2c M0 
 Any T N3 M0 
Stage IV Any T Any N M1 
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Current recommendations for treatment are based on the stage of 
melanoma and the ability to completely remove the lesion surgically with clear 
margins.  For all stages of melanoma wide local surgical excision is the primary 
treatment.43,47  Although an excisional biopsy is preferred for pathology 
evaluation often an incisional biopsy, superficial shave biopsy, deep scallop 
shave biopsy or punch biopsy is performed. 43,50 The goal of the biopsy is to 
pathologically confirm the melanoma diagnosis; whereas the goal of the wide 
local excision with a margin of clear tissue is to achieve long-term control of the 
disease and potentially a cure. 51 The type of biopsy technique used does not 
influence patient outcome. 52 What is essential is the removal of the lesion via 
wide local excision with clear margins.  Inadequate margins can result in local 
recurrence, metastasis and negatively impact survival. 53-55 The NCCN provides 
specific guidelines for the amount of tissue around a lesion that needs to be 
excised depending on the size of the lesion, referred to as the clear surgical 
margin. 47  Refer to Table 2.3.   
 
Table 2.3 
Recommendations for Surgical Margins 47 
 
Tumor Thickness Recommended Clinical Margins 
In Situ 0.5-1.0 cm 
<1.0 mm 1.0 cm 
1.01-2.0 mm 1-2 cm 
2.01-4.0 mm 2.0 cm 
> 4.0 mm 2.0 cm 
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Following the wide local excision a sentinel lymph node biopsy may then 
be recommended depending on the stage of disease.  The AJCC melanoma 
staging committee recommendation states “that sentinel lymph node biopsy be 
performed as a staging procedure in patients for whom the information will be 
useful in planning subsequent treatments and follow-up regimens. Specifically, 
the procedure should be discussed with (and recommended for) otherwise 
healthy patients who have T2, T3 and T4 melanomas and clinically uninvolved 
regional lymph nodes; the procedure should be recommended selectively for 
patients with T1b melanomas”. 18 If a positive lymph node is found then complete 
lymph node dissection should be completed and all additional areas of 
metastasis should be surgically removed. 47 These recommendations are based 
on the most current research in an area of great controversy, as it is still unclear 
whether a complete lymph node dissection increases overall survival. 28,56  
The effectiveness of non-surgical treatment is limited so it should not be 
considered unless surgical excision is not feasible. 57 If surgical removal of the 
lesion with clear margins cannot be obtained due the location of the primary 
lesion or if there is metastatic disease, then systemic treatment is warranted. 47 
Based on the NCCN guidelines for stage III and IV disease, additional treatment 
following surgery is recommended including observation, systemic therapy with 
interferon or clinical trial with a new therapy. 47 
Systemic therapy options can include radiation therapy, chemotherapy 
and/or immunotherapy.   Previously the melanoma treatment options were 
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sparse but in the last five years there have been considerable improvements with 
the addition of molecular targeted therapy. 41 In 2011 the Federal Drug 
Administration (FDA) approved systemic therapy with ipilimumab the only 
monoclonal antibody directed at cytotoxic T-lymph antigen. 47 As approximately 
half of patients with metastatic melanoma are BRAF positive the FDA approved 
BRAF kinase inhibitors; vemurafenib in 2011 followed by dabrafenib and 
trametinib in 2014.  These drugs were all approved based on months of improved 
overall and progression-free survival, but come with high-grade, adverse effects 
and thus are reserved for treatment of recurrent disease. 47 Despite these 
advances, chemotherapy and systemic therapy provide only modest response 
rates affirming that early-stage diagnosis with wide surgical excision remains the 
key to melanoma survival. 47,57,58  
 
Incidence, Prevalence and Mortality rates 
The incidence of melanoma in the US is increasing faster than any other 
preventable cancer. Between 2002 and 2012 incidence has increased by 1.4% 
annually with the average lifetime risk of developing melanoma at 2.1% in the US 
population. 7 In 2013 the overall age adjusted melanoma incidence rate was 21.8 
per 100,000 and this is expected to only increase as no primary prevention has 
been implemented and from 1982 to 2010 incidence rates doubled. 3,7 The 
increase in incidence is at least partially attributed to the increase in early-stage 
detection and UVR exposure through recreational activities. 59 Yet, the sharpest 
increase in incidence has been seen in low SES communities, where individuals 
are less likely to be screened, indicating that the increase may not be simply an 
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artifact of screening. 2 In all population groups over the past few decades the 
proportion of thin melanomas diagnosed has increased while thick melanomas 
have decreased. This may be influencing the overall reduced mortality rates. 60,61  
The prevalence of melanoma is also increasing due to the over 75,000 
new cases per year and only a 10% mortality rate.  In 2005 there were 723,416 
people living with melanoma and in 2013 this number had risen to 1,034,460. 7 
Non-Hispanic white men and women in the US carry over 95% of the burden of 
disease. 62 While the incidence rate from 1982 to 2013 has risen steadily, the 
mortality rate has remained stable at around 10%. 3,7,42 The overall survival rate 
in the US has increased over the last twenty years from approximately 82% to 
91%. 7 Generally, the 5-year survival of melanoma is over 90% with localized 
disease, but if the cancer spreads into the regional lymph nodes the 5-year 
survival is less than 50%, and with metastatic disease it is less than 10%. 45,47 
Survival is dependent in part on the stage and subtype of melanoma followed by 
the treatment provided. 27,45 
Looking more specifically at stages, based on the AJCC staging database 
through 2008, the 10-year survival for a stage IA lesion is 93% but only 39% for a 
stage IIC lesion. 18 Additionally, a study by Ward-Peterson et al examined 
185,219 melanoma cases from 1982 to 2011 and confirmed that the stage of 
diagnosis had a significant impact on hazard ratio. 63 They found that localized 
disease had a hazard ratio of 5.8 while regional disease had a hazard ratio of 
31.5 and metastatic disease had a hazard ratio of 169.5. 63 Beyond disease 
stage it is known that for localized disease survival is impacted by tumor 
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thickness, ulceration, mitotic rate, site, gender and age. 54 Survival is also 
negatively impacted by lymph node involvement with 5-year survival for stage 
IIIA, IIIB and IIIC at 78%, 59% and 40% respectively. 18 Meanwhile, the one-year 
survival of a stage IV melanoma is a dismal 62% for an M1a lesion, 53% for a 
M1b lesion and 33% for a M1c lesion. In stage IV disease, an elevated serum 
LDH level at time of diagnosis is a negative prognostic indicator with a 32% 1-
year survival rate compared to 65% in a patient with a normal serum LDH. 18  
Decades of research have established that melanoma incidence and in 
turn prevalence rates and often mortality rates, are also influenced by numerous 
factors at the individual and social level.  These include age, gender, race, 
ultraviolet radiation (UVR) exposure, SES, marital status, geographic location, 
tumor histology, tumor location, insurance status, access to health care, and 
prevention efforts of sun-protective behaviors, risk awareness and early detection 
efforts. 6,7, 14-25,64,65 The individual factors of age, gender, race and disease 
subtype will be outlined here and then followed by social determinants. Later in 
this chapter additional risk factors and prevention efforts will be discussed in 
detail.   
 
Age 
Age is an important variable in both incidence and mortality rates.  
Melanoma is predominantly found in non-Hispanic whites with the highest 
incidence in males and those adults over 75 years old. 1,19,47,66,67 Over the past 
few decades, incidence rates began to level off in those less than 65 while it 
increased in those over 65.  From 1983 to 2007, a 2-fold increase in incidence 
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was seen in men aged 60 to 64, whereas in men aged 75 to 79 there was a 4-
fold increase. 68 This increase is mostly attributed to the growth in the geriatric 
population. 25 Among the elderly, it has been found that minorities, those who are 
single or widowed, have more comorbidities, reside in rural areas and 
communities with less education and more poverty are especially at risk for late-
stage disease. 69 
Meanwhile, in young women where there has been an 800% increase in 
incidence from 1970 to 2009 that is attributed to risky health behaviors like 
tanning. 6,70 Early-stage melanoma is seen more commonly in women less than 
40 years old and more commonly in men after age 40. 16 Older people do have 
poorer survival rates as those older than 70 tend to present with lesions that are 
thicker, more ulcerated and have higher mitotic rates. 71 This increase in mortality 
is also attributed to higher cumulative UVR exposure, later stage at diagnosis 
and poor access to medical care. Meanwhile, the decrease in melanoma deaths 
in those less than 65 years old is credited to early detection and improved 
treatment. 62  
Balch et al noted that age is an independent prognostic variable in 
melanoma and may represent a decline in host mechanisms associated with 
advancing age. 17 Comorbidities are often linked with age, as with increasing age 
comes increasing health concerns. Studies have linked Parkinson’s disease, 
immunosuppression from organ transplant and HIV infections to an increased 
risk of melanoma. 72 Additionally, the variation in anatomic distribution of 
melanoma is age-dependent.  Older people more commonly develop head and 
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neck melanomas with chronic sun exposure and have few nevi, whereas younger 
people develop truncal melanomas dependent on sun exposure early in life and 
have many nevi. 73 
 
Gender 
It is estimated that in 2016 approximately 46,870 men and 29,510 women 
in the US will be diagnosed with melanoma. 74 In the US, melanoma is the fifth 
most common cancer in men and the seventh most common cancer in women.74   
Overall melanoma is more common in men with poorer survival rates than 
women for all stages and in all age groups. 74,75 In 2016 it is estimated that 
10,130 people will die of melanoma with 66% of these deaths occurring in 
males.74   Interestingly, in the US the overall melanoma incidence ratio by gender 
is age-dependent. For example, in women less than 49 years old, 1 in 206 will 
develop a melanoma lesion and only 1 in 297 men will. Contrast this to women 
older than 70 years old where 1 in 52 will develop a melanoma lesion while 1 in 
33 men will.74  
These statistics assist in explaining the finding that more than 50% of 
melanoma deaths are in white men older than age fifty. 2 Also, males tend to 
develop melanoma lesions on the head or neck while females develop lesions on 
the extremities or torso. 25 Younger age, female gender and specific anatomic 
sites, such as the upper limbs, are related to better overall survival. 45 A higher 
rate in men is attributed in part to lower rates of sun protection behaviors, less 
use of sunscreen and more time spent outdoors per lifetime compared to 
women.3   It has also been discovered that men are less likely to seek skin 
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cancer screening, report a concerning lesion or be concerned about previous sun 
exposure. 4 
 
Race 
Those at highest risk for melanoma have light skin pigmentation and 
blonde or red hair. 23 Thus, Caucasians account for over 90% of melanoma 
cases reported in the US. 76 The incidence of melanoma both early and late-
stage is highest among non-Hispanic whites even when adjusting for SES. 16 Yet, 
Hispanics, Asians and Blacks have higher percentages of late-stage disease. 6 
Although there has not been a change in the overall mortality rate over the past 
decades, there is inequity in the demographics of melanoma mortality. 6,45 For 
example, the overall 5-year survival of melanoma from 2005 to 2011 was 70% for 
blacks while it is 93% for whites. 65 This difference in survival is impacted mostly 
by the later stage of diagnosis seen in minorities. A study of 1,690 melanoma 
cases in Florida demonstrated that late-stage disease was more common in non-
Hispanic blacks and Hispanics at 52% and 26% compared to whites at 16%. 64 
Yet, even when diagnosed with localized disease a disparity in survival is present 
with 5-year survival at 86% for blacks and 97% for whites. 77 This difference in 
stage of diagnosis and survival in minorities is attributed in part to the location of 
the lesions (the majority of lesions are on non-exposed skin areas), decreased 
suspicion by clinicians and patients and limited access to health education 
resources or health care. 3,25 
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Subtype 
Although not as predictive as stage, the subtype of melanoma at diagnosis 
contributes to the prognosis.  Superficial spreading and lentigo maligna are both 
favorable subtypes with 95% 5-year survival rate. 45 Meanwhile, acral lentiginous 
has a poor prognosis with 5-year survival as low as 83% and is seen more 
commonly in minority populations. 6,45 The most dangerous subtype is nodular 
melanoma, comprising only 10% of all cases but is greater than 50% of all deep 
(> 2 mm) lesions.  Nodular lesions grow quickly and develop as new lesions that 
are difficult to screen for because they do not following the typical asymmetry, 
border irregularity, color, and diameter (ABCD) criteria. 78,79  
 
Social Determinants 
While the complex interplay of genetics and UVR exposure leads to the 
development of melanoma it is apparent that the incidence rate is influenced also 
by social factors. The effect of SES on melanoma incidence, disease stage and 
survival is well documented in the literature but this interaction is multifaceted 
and often difficult to measure. 6,80 Thus, contextual variables that have been used 
as surrogates for SES including education level, unemployment rates, poverty 
level, occupation type and median household income. 6 A contextual variable 
summarizes the characteristics of the individuals in the group. 81 Therefore, the 
contextual variable does not characterize the individual but the group as a 
whole.82   This may deliver insight into the individual that is not otherwise 
available and even more importantly offers community level information to 
individual health outcomes. 83  
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The best example of how individual and social factors are intertwined is 
UVR exposure and SES.  Increased UVR exposure through outdoor recreation 
and leisure is a product of SES itself. It is hypothesized that affluence increases 
geographic mobility as well as leisure time that is then linked to UVR exposure. 16 
This exposure to the sun is the only modifiable risk factor for melanoma 
development. 23 UVR exposure is often a personal decision but impacted by SES 
via education, occupation and geographic mobility. 6 It is unclear if SES affects 
melanoma independently or if SES is a proxy for UVR exposure. 84 Regardless of 
this relationship, it is known that SES continues to influence the incidence of 
melanoma even when controlling for age, gender, UVR exposure and race. 6 For 
example, an analysis of California data from 1988 to 2007 showed that Hispanics 
of lower SES had higher risk of thick tumors and nodular melanoma than 
Hispanics of higher SES indicating that SES impacts minorities as well. 2 
A review of over forty research articles on the influence of SES on 
melanoma by Reyes-Ortiz, Goodwin and Freeman explained that the positive 
social gradient of melanoma is a confounder of genetics, UVR exposure and 
increased screening. 6 Those cases of melanoma with high SES also tend to 
have a genetic predisposition to skin cancer through fair skin, light hair and 
propensity to get sun burns. 6 This is true in the US where over 90% of 
melanoma cases occur in Caucasians. 76   Winter vacations to warm locations 
and leisurely summers in the sun provide opportunities for increased UVR 
exposure among people with high SES. 6,61   Also, those with affluence and 
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access to health care are more likely to be screened for melanoma leading to 
earlier and more frequent detection. 6 
Education historically has been the most commonly used contextual 
variable for SES because it is easy to measure, commonly reported and stable 
throughout a lifetime. 83 To clarify the effect of education level on melanoma 
diagnoses Pollitt et al surveyed 566 newly diagnosed patients. 20 Those surveyed 
with lower education levels were more likely to report a belief that melanoma was 
not very serious and never thinking of themselves as being at risk. Lower 
education was also strongly associated with less knowledge about melanoma 
detection. Patients at all education levels appeared to have relatively equal 
access to health care but those without a college education were significantly 
less likely to have received a clinical skin examination. People without a college 
education were less likely to have talked with a physician about melanoma, been 
told they were at risk of skin cancer, instructed to keep an eye on a certain mole 
or instructed on how to look at their skin for signs of melanoma. Patients without 
a college education were also 3.4 times more likely than college educated 
patients to report competing health concerns with their melanoma diagnosis. 20 
Unemployment has also been used as a contextual variable for SES and 
appears to have a positive effect on melanoma rates. Counties with low 
unemployment were found by Singh et al to have the highest rate of melanoma 
when compared to high unemployment counties, incident ratio (IR) 30.1 and 23.1 
respectively. 16 However, studies have found unemployment to be less important 
than the type of occupation. There is a paradoxical relationship in which work-
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related UVR appears to lower the risk of melanoma in outdoor workers compared 
to indoor workers.  This may be because continual frequent exposure of sun 
poses less risk for development of melanoma than the episodic infrequent, 
intense exposures that may cause sunburns. 61 For example, a few studies have 
noted an increase in melanoma in airline crews related to their increased 
opportunity for recreational sun exposure. 86,87 
It has also been noted that geographic location effects melanoma 
incidence and this is thought to be due to the social aspects of topography. A 
geographic location often embodies health care access, demographic factors of 
the population and UVR exposure. 15,16,85 For instance, when comparing 
metropolitan and rural areas in North Carolina it was noted that rural patients 
were older and more likely to live in poverty. 85 When Singh et al compared 
melanoma incidence between rural, urban and metropolitan areas, they found 
the highest incidence for all melanoma cases in metropolitan areas (IR 30.5), 
followed by urban (IR 25.4) with the lowest rate in rural areas (IR 23.2, p 
<0.05).16 This trend was noted also for early-stage disease, but for late-stage 
disease metropolitan and rural incidence rates were equivalent. Yet, upon 
multivariable analysis, county population was not significant for melanoma 
incidence. 16 Higher age specific rates of melanoma are also seen in areas of the 
US with higher UVR exposure. 15 Alaska, for example, had the lowest rate of 
melanoma from 2002 to 2006 with 13/100,000 cases compared to Hawaii with 
62/100,000 cases. 67 Additionally, as expected, an analysis of UVR exposure in 
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the US found that both early and late-stage melanoma incidence rates were 
significantly higher in counties with high UVR levels compared to low levels. 15 
 
Risk Factors, Prevention and Screening  
Development of a melanoma lesion involves a complex and not well-
understood interaction between individual and social factors. Individual factors 
include the nonmodifiable risk factors of age, gender, race, genetics, family 
history of melanoma, personal history of melanoma, lighter skin pigmentation, 
blond or red hair, blue or green eyes, increased number of nevi and a tendency 
to get sun burns. Of these risk factors, hair color and pigmented nevi are the 
strongest and most consistent predictors of risk. 23 Significant study has been 
given to modifiable risk factors including smoking, diet, hair dyes, fluorescent 
lighting, hormone therapy and stress, but no association with melanoma has 
been found. 61,80 A meta-analysis by Jiang et al shows some studies with an 
association between obesity and melanoma incidence and mortality and some 
without. 80 Likely though, body mass index is playing a role in screening where 
those with an increased body mass index have decreased screening behaviors. 
80 To date, the single modifiable risk factor is sun or UVR exposure. 23 Intense 
and intermittent sun exposure with sun burns especially before the age of fifteen 
is a strong predisposing risk factor for melanoma later in life. 23 UVR exposure via 
natural sunlight or artificial tanning is correlated with SES, as affluence affects 
leisure time and the ability to travel to areas with higher UVR radiation. 84 
Despite significant research there is incomplete evidence regarding the 
nature, timing and extent of UVR exposure and its relationship to melanoma 
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development. 15,23 It is acknowledged that there is a difference in melanoma 
subtype based upon chronic sun exposure and non-chronic sun exposure but 
this will remain a difficult area of research due to the limited ability to measure 
sun exposure in a retrospective study and the lack of cohort studies due to the 
rarity of melanoma cancers. 37,88 Various aspects of sun exposure have been 
studied including smaller swimsuits, population migration to the equator, thinning 
of the ozone layer and increased tanning bed use. 61,89 UVA and UVB exposure 
are known to cause melanoma with UVB exposure coming from sun exposure 
and tanning bed use. 23,61 It is known that sunburns at a young age are a risk as 
is cumulative sun exposure. 25 A meta-analysis of over fifty articles on sun 
exposure and melanoma risk noted that intermittent sun exposure and sunburns 
are risk factors but surprisingly high occupational sun exposure is not. 88 
A common form of intermittent sun exposure is tanning beds as 
approximately 30 million people use tanning beds each year. 89 An analysis of US 
tanning bed use found that approximately 35% of adults, 55% of university 
students and 19% of adolescents have used a tanning bed. Regardless of age, it 
is known that women tan more often than men. 90 Despite the tanning bed 
industry insistence that tanning beds are safe, substantial evidence has indicated 
an association between tanning bed use and melanoma. 23,89,91-93 The 7 to 20 
year lag between UVR exposure and development of a melanoma lesion further 
complicates analysis. 89,91 Despite this long time period, numerous studies have 
found that a modest, yet significant increase in risk from tanning bed use. 94 The 
tanning bed industry states that tanning beds emit more UVA radiation than UVB 
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but the National Toxicology Program states that both UVA and UVB are 
reasonably anticipated to be human carcinogens. 95 A study by Ting et al found 
that women less than 45 years old with a history of tanning bed use had a three-
fold increased odds of melanoma compared to those women who reported never 
using a tanning bed. 92 The population attributable risk of tanning bed use is 2.6% 
to 9.4% of melanoma cases. 96 
Primary and secondary prevention of melanoma through sun-protective 
behaviors, risk awareness and early detection efforts are crucial. Sun-protective 
behaviors include avoiding sun exposure and tanning beds, wearing protective 
clothing and liberal use of sun screen. 23,25 The protective effect of sunscreen is 
only circumstantial, but practical evidence would suggests that since UVR is a 
risk factor for melanoma and sunscreen decreases UVR absorption then 
melanoma would be prevented. 97,98 Teaching these protective behaviors to 
children is fundamental as the risk for sunburns is most acute during early 
childhood.  Additionally, behavioral patterns and attitudes toward sun exposure 
develop early on, determining both adolescent and adult behaviors. 23 To protect 
children, the World Health Organization and the International Commission on 
Non-Ionizing Radiation Protection recommend against those less than eighteen 
years old from using artificial tanning devices. 99,100 In the US, California and 
Vermont have been the first states to ban the use of tanning beds by people less 
than eighteen years old. 101 
The need for public and health care provider education regarding the risk 
and recognition of melanoma lesion was acknowledged in 1985 with the 
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development of the asymmetry, border irregularity, color and diameter (ABCD) 
criteria. 24 The ABCD criterion describes a suspicious lesion as one that is 
asymmetric, with irregular borders, has multiple colors and with a diameter 
greater than 6mm.  This acronym was developed to be a simple tool for both the 
general population and medical community to recognize thin melanoma lesions.  
The ABCD criterion has been shown to be both sensitive and specific for 
melanoma. After decades of use the ABCD criteria has expanded to the ABCDE 
criteria with the addition of the term, evolving.  Evolving recognizes the change in 
shape, size or symptoms of a lesion, which is especially important for nodular 
melanomas. 24 This effort to increase awareness of the risk of melanoma has 
increased screening rates and the detection of earlier stage lesions. 59,62,101 
Research has shown that even a one-time instruction regarding the ABCDE 
criteria can improve recognition of a melanoma lesion both in the general 
population and by clinicians. 102,103 Meanwhile, an increased awareness of 
melanoma was associated with both a decreased time to seek medical attention 
for a suspicious lesion and thinner lesions. 104 Education of the public is important 
because patients find the majority of melanoma lesions themselves although if 
found by a clinician the lesion tends to be thinner. 25,105 
To date, there has been no community-based randomized trial conducted 
to demonstrate the decrease in mortality from screening asymptomatic persons 
for melanoma.  This lack of evidence is due to the low rate of melanoma mortality 
and high costs associated with such a study. Thus, no recommendation for 
routine population-based screening can be made and the US Preventative 
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Services Task Force reports that there is insufficient evidence to recommend 
regular skin checks on the general population. 4,5 Additionally, there are no 
recommendations published for eye exams, oral exams or pelvic exams to 
monitor for mucosa melanoma lesions. 44 Following melanoma treatment there is 
also a lack of clarity on recommended long-term follow up.  It is estimated that 
there is an increased risk of developing a second primary melanoma of 8-10%, 
yet intensive long-term follow up beyond five years is likely not cost effective. 106-
108  
Despite the lack of evidence, the American Cancer Society recommends 
that all people between the ages of twenty and forty be screened via clinical skin 
assessment for melanoma. 1 At the same time, the American Academy of 
Dermatology has developed a personal screening program, Body Mole Map, 
recommending that patients perform skin self-assessments and record changes. 
However, they do not specify the frequency of self-assessments, nor do they 
specify how often clinician provided exams should be completed. 109 With the 
community and clinicians receiving these mixed messages regarding screening, 
it is not surprising that participation in screening is limited. 
It is known that approximately 10% to 25% of the US population practice 
regular skin self-examinations. 110 It is estimated that a skin assessment by a 
dermatologist is 89% to 97% sensitive for melanoma diagnosis. 23 Yet, only 8% 
to 21% of the population receives annual clinical skin exams. 111-113 A study by 
Swetter et al noted that thinner lesions were found in people who the year before 
had regularly examined their own skin, consulted a physician at least once and 
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received a full body skin exam by a clinician. 105 But, interestingly in this study the 
benefit of the full skin exam by a clinician was limited only to men over sixty; in 
this age group there was a 4 times greater odds of a thin tumor compared to men 
who did not receive a full skin exam by a clinician. 105 Meanwhile, it is known that 
females and those with continuous Medicaid insurance are more likely to seek 
screening and care for a concerning lesion, while at the same time race, SES, 
health insurance status and access to health care all further influence screening 
behaviors. 6,20,66,114 For example, in the Appalachian area of Kentucky access to 
health care, limited finances and low education levels are all known barriers to 
getting cancer screenings. 115  
Additionally, the health care system itself also influences melanoma 
screenings.  Many experts argue that primary care physicians are critical to 
melanoma control but others question if they have appropriate training or enough 
time to conduct adequate skin exams. While only 13% of the population reports 
having a dermatologist, 85% report seeing a physician within the last two 
years.116 As the majority of health insurances require a referral to see a 
dermatologist, this reinforces the role of the primary care provider in evaluating 
suspicious lesions. 4 A meta-analysis noted that from 1987 to 2004 the number of 
primary care physicians who performed full-body skin exams actually 
decreased.117   Time constraints, competing comorbidities and patient 
embarrassment were listed as barriers to completing full skin exams in a survey 
of 1600 physicians. 104 An analysis of the National Ambulatory Medical Care 
Surveys from 2005 to 2010 found that a patient was more likely to receive a skin 
 32 
examination at a primary care office if they saw a physician assistant or nurse 
practitioner. 118 With such inconsistency in screening guidelines and practice it is 
apparent that subsets of the population could be at risk for later stage diagnosis.  
 
Disease Stage   
The stage at which melanoma is diagnosed directly impacts prognosis and 
survival. 27 Melanoma is staged by the AJCC cancer-staging manual and 
classified into stages I through IV. These stages are frequently categorized into 
early and late-stage with early-stage including stages I and II while late-stage 
includes both regional disease, stage III, and metastatic disease, stage IV. 21,47,49 
SEER data from 2009 indicated that the 5-year survival for localized, regional 
and metastatic melanoma is 98%, 62% and 15% respectively. 21 Over the past 
few decades there has been an increase in proportion of thin lesions diagnosed 
with a corresponding decrease in thick lesions, which is likely impacting the 
decreasing mortality rate. 60,61 
Social factors that have been shown to influence the stage in which a 
lesion is diagnosed include SES, geographic location, employment or 
occupation, marital status, health insurance status, physician population ratio and 
access to health care. 6,14-16,20-22 The effect of SES on melanoma is two-sided 
with high SES linked to high incidence rates with early-stage disease and low 
SES linked to lower incidence rates but poorer outcomes. 6,16 The positive social 
gradient of melanoma disease stage is well supported in the literature via 
multilevel analyses, case-control studies and surveys. 2,6,14,16,20,66,84,119 Singh et al 
provided the most comprehensive review of SES with a multilevel Poisson 
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regression of 130,359 melanoma cases from the 2004 to 2006 SEER data which 
found higher county incidence ratios for all cases of melanoma where there is 
lower poverty, a higher education level, a higher median household income and 
lower unemployment. 16 Low poverty counties had a significantly higher IR of 
melanoma compared to high poverty counties (IR 27.6 vs 15.9, p <0.05). 16 Also, 
the incident rate for all cases was 47% lower in counties with low education 
levels compared to those with higher education levels. For early-stage, late-stage 
and all cases of melanoma the incidence rates were highest in counties with a 
high median household income. 16  
Although melanoma is unique with a positive social gradient this cancer is 
similar to other cancers in that poverty level is associated with late-stage 
disease. A study by Greenlee et al evaluated 2 million cancers in the US from 
1997 to 2000 and melanoma had a two times increased odds of late-stage 
disease when comparing the counties with the highest poverty to the lowest. 120 
Hu et al who completed a spatial analysis of melanoma cases in Florida 
confirming this juxtaposition where for every 1% increase in population living in 
poverty they noted a 2% increase in late-stage melanoma cases. 121 A person’s 
geographic location also has a social influence on disease stage with early-stage 
diagnosis more common in urban areas where the counties have higher 
education levels, higher incomes, less poverty and higher rates of health 
insurance. 15  
A study by Youl et al of 3,762 cases and 3,824 controls evaluated the 
impact of SES on melanoma lesion thickness by evaluating education, 
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employment status and marital status. 122 The multinomial regression model 
found the variables of not working, not married and lower education level to each 
be significantly associated with an increased risk of having a thick melanoma 
lesion. Additionally, not having a clinical skin examination within three years of 
diagnosis was associated with a 45% increased risk of a thicker lesion. (RRR 
1.45, p <0.001) 122 Education is known to influence position in society, access to 
health care, access to health information and therefore health decision making. 
Youl et al suggests that a clinical skin examination may be a mediator between 
education and lesion thickness. 122  
One factor that has been found to be protective for melanoma diagnosis 
and survival is marriage or living with someone. 122,123 Van Durme et al noted a 
53% increased risk of late-stage diagnosis of melanoma in unmarried people. 124 
A study on people over 65 years old by Reyes-Ortiz et al described that being 
single or widowed increased the risk of late-stage melanoma diagnosis and 
significantly lowered survival. 19 McLaughlin, Fisher and Paskett evaluated the 
effect of marital status on the stage of diagnosis of 192,014 melanoma cases 
from 1973 to 2004. 21 Among men, the odds of late-stage melanoma versus 
early-stage was 1.31 for widowed, 1.56 for those never married and 1.60 for 
those separated or divorced.  For women the odds of late-stage versus early-
stage melanoma was 1.93 for widowed, 1.25 for never married and 1.57 for 
divorced or separated. 21 
These findings highlight the relationship between gender and marital 
status revealing the protective effect of marriage for both sexes. These 
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differences are considered to be due to the social support, insurance status and 
prompting to access healthcare that is received from a spouse. The increase in 
access to health care noted in married people could also be due to the spouse 
spotting a lesion, peer pressure to seek screening or assistance from a spouse 
for daycare or transportation to seek a clinical evaluation. 21 
To have access to the US health care system the individual needs health 
insurance coverage and the community needs an adequate health care 
workforce. Having health insurance in the US allows one to afford screening and 
treatment. Research has shown that having health insurance increases 
screening rates, which in turn leads to an increase in measured incidence 
rates.6,20,66 Analyses of those diagnosed with melanoma have shown that lack of 
insurance or insurance with Medicaid or Medicare increases the risk of late-stage 
diagnosis. 125 Meanwhile, a study of the primary care physician supply in Ohio 
found a decrease in late-stage melanoma cases associated with an increase in 
physician density but most significantly among those with insurance. 126  
Roetzheim et al reviewed the supply of dermatologists and family 
physicians in Florida and earlier detection of melanoma was associated with an 
increase in both types of provider. 22 They establish that for each additional 
dermatologist and family physician per 10,000 populations there was an 
increased odds of early diagnosis by 39% and 21% respectively. 22  Another 
study evaluated the distance a patient would have to travel to see a clinician in 
North Carolina and found that for every one-mile increase in distance there was a 
0.6% increase in Breslow thickness; therefore, a ten-mile or longer drive to a 
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clinician was associated with a clinically significant increase in melanoma lesion 
thickness.  Interestingly, there was a decrease in Breslow thickness for those 
patients who drove over 120 miles to seek care, which supported previous 
research showing a protective benefit for those patients who have the ability to 
travel long distance to seek superior health care. 85,127  
Of interest, those who resided in a county that had a dermatologist 
traveled on average 8.3 miles less than those who resided in a county without a 
dermatologist. This impact was seen even if the patient did not actually see the 
dermatologist suggesting that the presence of a dermatologist was actually a 
marker of an increase in supply of health care providers in general. 85 A positive 
effect on early-stage of melanoma diagnosis is seen for increased physician 
density and recent primary care physician visit. 15,116 Additionally, an increase in 
dermatologist density is associated with decreased melanoma mortality. 128 
These studies confirm the social and geographic barriers that then affect 
melanoma disease stage.  
 
Treatment 
 
Surgery is the only potentially curative treatment for melanoma. Surgery 
for localized disease, stages I and II, includes wide local excision of the primary 
tumor and may include excision of lymph nodes. A biopsy followed by wide local 
excision is critical for diagnosis, staging and disease free survival. 129 As Breslow 
thickness increases overall survival decreases. A patient with a lesion less than 
1mm has a greater than 85% 5-year survival, while a patient with a lesion thicker 
than 4mm has less than 50% 5-year survival rate. 85 For localized disease, 
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Breslow tumor thickness, ulceration and mitotic rate predict disease outcome. 58 
The NCCN provides melanoma treatment guidelines that are supported by an 
abundance of clinical trials; they have determined that at least 1 cm and no more 
than 2 cm of clear surgical margins is adequate treatment. 47,51,130 Refer to Table 
3.1.   These recommendations are considered the standard of care treatment 
that should be provided to all patients unless not appropriate for a specific patient 
based on their medical situation. 47 It is known that inadequate margins result in 
higher rates of loco-regional metastasis but wide margins lead to increased 
morbidity and a poor cosmetic outcome. 51,53 Therefore the goal of surgical 
treatment is to optimize local control with potential cure while minimizing 
morbidity. 51 
The recommendation to provide a clear margin of 1-2 cm around a 
melanoma lesion is due to the propensity of melanoma to disseminate and recur 
locally.  Local reoccurrence occurs in approximately 5% of cases but in lesions 
larger than 4mm can occur in up to 12% of cases. 131,132 Local recurrence does 
not occur only from inadequate surgical excisions but can be a manifestation of 
an aggressive, ulcerative and thick primary lesion. 54,131 On average local 
recurrence is seen in 10.5% of head and neck melanomas compared to only 
3.8% in trunk and extremity lesions. 133 Local recurrence is usually associated 
with the development of systemic metastasis and a poor prognosis of less than a 
5% chance of survival at 10 years. 131 
Several studies have confirmed that inadequate surgical margins are 
correlated with local recurrence. 51,53,54,58,134 It is known that in head and neck 
 38 
lesions positive margins are seen in 6-21% of cases. Risk factors for positive 
margins include ulceration, increased tumor thickness, recurrent tumor and 
advanced age. 133 A study by Foster, Velasco and Hieken 2008 noted recurrence 
of disease in 36% of patients with inadequate margins compared to 12% of those 
with adequate margins. 134 However, these studies have not shown a significant 
correlation between surgical margins, recurrence of disease and survival.51,53,54,58  
A Cochran review by Sladden et al of five randomized control trials of wide 
local excisions of primary cutaneous melanomas noted that none of the studies 
showed a statistically significant difference in overall survival when comparing 
narrow versus wide excisions. Of note, the study by Balch et al, which compared 
narrow margins of 2 cm to wide margins of 4 cm, was used in developing the 
most recent NCCN guidelines that established that a margin larger than 2 cm 
does not improve patient outcomes. 54 Even with excessively wide margins of 2-4 
cm, Sladden et al explained that the point estimate for overall survival favored 
wide excision by a small degree (HR 1.04). 58 The inability to demonstrate the 
effect of clear margins on survival is attributed to the lack of size and power of 
the studies due to the low rate of local reoccurrence and even lower effect of 
clear margins on melanoma specific deaths.  Additionally, when local 
reoccurrence does occur it does not cause metastasis that impacts survival. 51,55 
As the effects of inadequate margins is still under investigation the current belief 
is that inadequate margins increases the risk of local reoccurrence and therefore 
may be associated with increased mortality. 53-55 
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Despite the abundant effort to provide medical guidelines, research in the 
United States shows that generally medical guidelines are followed only 55% to 
75% of the time. 135,136 Although these guidelines were not developed for strict 
adherence this low rate is surprising.  More concerning is whether variation in 
adhering to these guidelines is also a sign of inequity in health outcomes. Studies 
have shown that this noncompliance with cancer treatment guidelines is present 
for other cancers as well.  For example, adherence to recommended 
chemotherapy for breast, lung and colon cancers has been shown to occur more 
frequently in higher SES areas. 137-139 This may be due to availability of treatment 
because seventy percent of chemotherapy is provided in the outpatient setting.140 
Whereas for melanoma, Reyes-Ortiz noted that younger age; marriage and SES 
were independent predictors of receiving chemotherapy treatment. 141  
Looking at melanoma surgical treatment, Cormier et al provided an 
analysis of 1998 to 2001 SEER data on 18,499 cases of melanoma and found 
that 31% of stage 1A, 40% of stage IB and II and 69% of stage III cases were 
provided surgical treatment according to the NCCN guidelines. 28 An analysis by 
Wasif et al of 35,126 melanoma cases from SEER data from 2004 to 2006 found 
noncompliance with surgical margins in 68% of cases.  Less than a 1 cm margin 
was resected in 62% of T1, 44% of T2, 41% of T3 and 42% of T4 cases. 142 
Wasif et al then completed an analysis of 2004 to 2008 SEER data that showed 
that only 40% of the 60,194 cases underwent wide local excision with at least a 1 
cm margin. 153 A community-based study of 252 clinically node negative 
melanoma cases found that 87% of Tis and T1 tumors followed NCCN treatment 
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guidelines while only 60% of T2-T4 tumors were compliant. 143 These studies 
demonstrate the lack of surgical treatment adherence in melanoma. If there were 
better adherence to melanoma treatment guidelines it would most likely improve 
morbidity and mortality.   
While there is an abundance of research on the factors that influence 
melanoma incidence and mortality the research on surgical treatment adherence 
is anemic. Research on the variance in surgical treatment for melanoma includes 
stage of disease, anatomic site of lesion, age, race, poverty, marriage, 
geography, health care system and type of health care 
provider.28,53,54,85,123,129,132,143-149  
The lower the stage of disease the more likely inadequate margins will be 
excised revealing a bias that localized disease is less concerning. 53 Meanwhile, 
numerous studies have noted that the anatomic site of a lesion, most commonly 
the head and neck, plays a significant role in lesions being left with inadequate 
margins. 145 This is understandable due to cosmetic concerns but this places the 
patient at risk as T3 and T4 lesions most commonly have positive margins and 
head and neck lesions have the poorest prognosis compared to other anatomical 
sites. 54,148 
The age of the patient is likely a corollary for comorbidity and has been 
consistently associated with noncompliance of treatment recommendations. 142 
Numerous studies have found that the risk of a patient not being provided the 
recommended melanoma surgical treatment is associated with older age, 
especially greater than 80 years. 28,132,142,145 One study determined that 
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compared to those aged less than 35 years, patients’ aged 65 to 74 had 1.37 
odds of inadequate treatment while those over 75 years had 2.38 odds. 28 
Another study discovered that the odds that a doctor would not comply with 
treatment guidelines increased 2.6% per life-year. 132 
The effect of age on treatment is understandable but inadequate surgical 
treatment of melanoma has also been associated with race. 142,146 The 
multivariate analysis by Wasif et al of the 2004 to 2008 SEER data revealed that 
the race of “other” had a three times greater odds of inadequate surgical margins 
compared to the white race group.  Also, blacks had a 1.59 odds and the “other” 
race group had a 2.81 odds of noncompliance with sentinel lymph node biopsy 
(SLNB) recommendations compared to whites. 142 An analysis by Collins et al of 
melanoma surgical treatment from 1973 to 2004 on SEER data showed that 
blacks were less likely to receive any surgical treatment but more likely to 
undergo amputation. 146 This analysis of over 150,000 cases also revealed that 
melanoma specific and 10-year overall survival of blacks was poorer than for 
whites regardless of surgical treatment. 146 
 The only study to date on SES and surgical treatment, Al-Qurayshi et al 
analyzed 2,765 discharge records from patients who underwent skin excisions 
and revealed that patients with low annual incomes were more likely to be 
treated in a non-teaching, rural or low volume hospital compared to high annual 
incomes. 144 At the same time, low-income patients and Medicaid patients were 
more likely to be treated by a low volume surgeon. 144  
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While poverty appears to negatively affect treatment, marriage seems to 
have a protective effect, as those separated, divorced or widowed were less 
likely to receive surgical treatment per the NCCN guidelines. 28 Place of 
residence also impacts surgical treatment as a comparison of rural and urban 
counties noted that those in rural counties had a 13% decreased odds of 
receiving SLNB compared to those residing in urban counties. 147 A study by 
Martinez et al supports this finding noting that residents in the Southern United 
States are 46% less likely to receive a SLNB compared to the Western United 
States. 150 State specific variations were also dramatic with 36% of Connecticut 
cases and 76% of rural California cases with inadequate margins.53 Meanwhile 
those residing in the state of New Mexico had an almost 4-fold increase in odds 
of non-adherence to surgical treatment guidelines compared to those in the city 
of San Francisco-Oakland. 28 
Meanwhile, various studies show that two other variables that could add to 
the discrepancy in melanoma treatment are the health system itself and the type 
of health care provider. 85,143,149 There are differences in the health care provided 
in small community hospitals and large medical centers. To this point, a study by 
Rivard et al hypothesized that the large referral cancer center would better 
adhere to the NCCN melanoma treatment guidelines. 149 They found instead a 
decreased adherence to the wide local excision guidelines but better adherence 
to the SLNB guidelines in the referral cancer center compared to outside the 
centers.  The diminished adherence to the wide local excision guidelines was 
attributed to more complex cases referred to their center and outside research 
 43 
indicating that less experienced cancer centers tend to take excessive surgical 
margins. Of interest, the cancer center itself did significant impact surgical 
treatment provided but the overall survival was not significantly different. 149 
Since melanoma treatment is provided by a wide variety of health care 
providers it makes sense that this would impact the treatment given. A study of 
melanoma treatment by Stitzenberg et al in North Carolina revealed that the 
health care provider and their practice patterns influenced the treatment offered, 
which may influence patient outcomes. 85   Particularly, they noted that surgeons 
affiliated with multidisciplinary melanoma programs were more likely to provide 
sentinel lymphadenectomy while those affiliated with academic centers were 
most likely to have access to clinical trials. 85 Another study evaluated the 
treatment provided at one community teaching hospital and despite easily 
accessible standards, physician education seminars and weekly multidisciplinary 
tumor board conferences there was a wide variation in melanoma treatment. 143 
Specifically, compliance with the NCCN guidelines for surgical margins was 
dramatically different between non-surgical oncologist and surgical oncologist, 
with 95% and 38% respectively. 143 These studies demonstrate that a wide 
variety of intentional and unintentional factors may be influencing melanoma 
surgical treatment.  
 
Conclusion 
As the rate of melanoma continues to rise there is an urgent need to better 
understand the risk factors, individual and social that define the population most 
at risk. This literature review demonstrates that those diagnosed with late-stage 
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melanoma are likely a vulnerable sub-population. Additionally, this literature 
review highlights inequity in health care delivery that needs further clarification. 
This captstone hopes to add to the literature on the social determinants of health 
that may be impacting late-stage disease diagnosis and non-adherence to 
surgical treatment guidelines. The purpose of this capstone is to help guide 
further public health interventions for melanoma in Kentucky.  
This concludes the comprehensive literature review of melanoma 
pathophysiology, staging, treatment, incidence, prevalence, mortality, risk 
factors, prevention, screening recommendations and discussion of the factors 
that have been shown to effect melanoma stage of diagnosis and adherence to 
surgical treatment guidelines. The following two chapters will encompass paper 
one which analyzes the factors influencing diagnosis of late-stage melanoma and 
paper two which analyzes the factors influencing non-adherence to melanoma 
surgical treatment guidelines for early-stage lesions.  
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Chapter III 
Individual and Social Factors Associated with Late-Stage Melanoma 
Diagnosis in Kentucky 
 
Introduction 
Malignant melanoma is the most deadly form of skin cancer, yet it still has 
a good prognosis with a 90% survival rate. 32,45 This high survival rate is because 
85% of melanoma lesions are diagnosed at an early-stage.  The 5-year survival 
rate for localized, regional and metastatic melanoma is 98%, 62% and 17.9% 
respectively. 7 Over the last few decades the incidence of melanoma has steadily 
risen. The age-adjusted incidence rate of melanoma in the US is 21.8 cases per 
100,000 population while the age-adjusted mortality rate is 2.7 per 100,000. 7 
Meanwhile, in Kentucky the age-adjusted incidence rate of melanoma is 24.3 
cases per 100,000 population while the age-adjusted mortality rate is 3.4 per 
100,000. 7  
 Unlike other forms of cancer, melanoma is most likely to occur in those 
with a higher socioeconomic status (SES) and generally is considered a disease 
of wealthy white individuals. 6 Despite this, it is known that people with lower 
SES, regardless of race, are more commonly diagnosed with an advanced 
disease stage. 6   Also, earlier detection of melanoma lesions has been 
associated with physician density of both family physicians and dermatologists. 22 
Due to these disparities, it is important to determine how the characteristics differ 
between those diagnosed with early-stage and late-stage melanoma.  
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The best indicator for melanoma survival is the stage in which the lesion is 
diagnosed. 26 Melanoma is staged first by determining the size of the lesion, 
extent of lymph node involvement and if the tumor has metastasized. 47 Using 
this information, the American Joint Committee on Cancer (AJCC) staging 
manual then categorizes the lesion into stage I through IV. 48 Often these stages 
are further merged into early (stage I and II) and late (stage III and IV). 21 Refer to 
table 3.1. The stage at which a melanoma lesion is diagnosed then determines 
the treatment course and outcome of the disease. 47 
The factors that influence the stage in which a melanoma lesion is 
diagnosed have been an area of significant study. The literature elucidates the 
influence of individual variables such as risk awareness, ultraviolet radiation 
(UVR) exposure, age, gender, race, marital status, tumor histology, tumor 
location and health insurance status on melanoma disease stage. 15,17-
19,21,23,25,74,125 Additionally, the influences of geographic region, SES and health 
care access have been established. 6,15,22 SES itself and the link between SES 
and individual health is difficult to measure, so surrogate measures are 
utilized.6,83  
Education and poverty are often used as indicators of SES as education is 
usually a stable marker throughout life and poverty has been associated with 
several health outcomes. 83,152 Several studies have found an association with 
both low education levels and high poverty levels and late-stage melanoma 
lesions. 16,121,122,152   
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In addition to SES, the inability to access the US health care system is 
associated with diagnoses of later stage melanoma. 125,126 Accessing the US 
health care system is complex with the anemic physician workforce at the center 
of the crisis. In 2015 the American Academy of Medical Colleges (AAMC) 
reported that the demand for physicians continues to grow faster than the supply 
leading to a projected deficit of up to 90,400 physicians by 2025. 153 The 
shortage of dermatologist is expected to only continue, especially in rural areas, 
as the incidence of skin cancer increases and the capacity for training programs 
stagnates. 154  
Kentucky is an exceptional population to study the effect of SES and 
physician density on melanoma disease stage. With a majority white population, 
Kentucky has an above average rate of melanoma and a high mortality rate. 155 
At the same time, Kentucky has higher rate of poverty and wider variance in the 
percentage of the population by county without a high school education 
compared to other US states. 156 Furthermore, this rural state ranks in the bottom 
one-third of states for active primary care physicians per 100,000 population. 157 
 The purpose of this paper is to assess for any associations between 
individual and social variables and late-stage melanoma in white non-Hispanic 
Kentuckians from 1995 to 2013. We hypothesize that late-stage diagnosis is 
associated with an increase in poverty level, decrease in education level and 
decrease in physician density. This study intends to lend insight into the high 
mortality rate in the state by identifying characteristics of those diagnosed with 
late-stage disease.  
 48 
Methods 
Study population and data resources 
Data on individual level variables were obtained from the Kentucky Cancer 
Registry (KCR) while community level variables were attained from the United 
States Census Bureau and the Kentucky Department for Public Health. The KCR 
is a statewide, population-based registry funded by the National Cancer 
Institute’s Surveillance Epidemiology and End Results (SEER) program and the 
Centers for Disease Control and Prevention’s National Program of Cancer 
Registries. 158 The KCR has 99% case ascertainment and has received gold 
certification from the North America Association of Central Cancer Registries 
each year since formal certification was established. 159 
All reported melanoma cases from non-Hispanic whites, 18 years or older 
from 1995 to 2013 were collected. Only non-Hispanic whites are described in this 
study due to the limited number of cases in other race groups. Cases that were in 
situ lesions or non-primary tumors were excluded. This provided data on 10,109 
cases including individual data on age, gender, marital status, year of diagnosis, 
anatomic site of lesion, health insurance status, rural/urban, Appalachian/non-
Appalachian and stage at diagnosis. 
The 2000 United States Census Bureau provided county level data on 
percentage with high school education and percentage below the poverty 
level.8,11 The Kentucky Department of Public Health provided 2006 physician 
licensure data with number of all-physicians, family practice physicians and 
dermatologists, in each county. 12 To determine the physician density the number 
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of all-physicians, family physicians and dermatologists, per 10,000 population by 
county was then calculated with the 2006 US Census Bureau intercensal 
population estimates. 159  
 
Outcome and Independent Variables 
The outcome variable of interest is disease stage: early versus late. Stage 
at diagnosis was categorized into early and late-stage with early-stage as 
referent and defined as stage I and II lesions while late-stage was defined as 
stage III and IV lesions. 
The independent variables of main interest are poverty level, education 
level and physician density. The percentage of the county below the poverty level 
and percentage with a high school education are provided as continuous 
variables. Physician density is evaluated with the continuous variables of all-
physicians, family practice physicians and dermatologists. Total physicians was 
applied as melanoma is diagnosed by many types of physicians not only family 
practice physicians and dermatologists.  
The year of diagnosis was categorized into five groups with 2013 to 2010, 
2009 to 2007, 2006 to 2003, 2002 to 1999 and 1998 to 1995.  Gender is 
categorical with male and female. Age was categorized into three groups with 65 
and older, 64 to 35 and 34 to 18 years. Marital status is also categorical with 
married/partner, single, widow, separate/divorced and unknown. Health 
insurance status was categorized where primary payor types were grouped, with 
private insurance, uninsured, Medicaid, Medicare and unknown. Geographic 
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region includes two measures, urban/rural and Non-Appalachian/Appalachian. 
Urban is defined as Beale codes 1 through 3 while rural is defined by Beale 
codes 4 through 9. Non-Appalachian is defined by counties defined as non-
Appalachian. 160 Anatomic site of the lesion is categorical based upon the area of 
the body.  
Statistical Analysis 
Descriptive statistics were used to describe the study population and the 
distribution of variables for all cases, early-stage and late-stage. A graph 
displaying the trend in melanoma incidence from 1995 to 2013 for early and late-
stage disease by year of diagnosis was made. The proportion of the study 
population that died was calculated by early and late-stage disease and by 
gender.   
Logistic regression was used to evaluate the unadjusted associations 
between each covariate and early-stage and late-stage disease groups. 
Covariates include age at diagnosis, gender, marital status, year diagnosed, 
anatomical site of lesion, health insurance status, urban/rural, non-
Appalachian/Appalachian, poverty level, education level, and physician 
population ratio for total physicians, family practice physicians and 
dermatologists. The resultant estimated odds ratios (OR) and 95% confidence 
interval were reported. All significant variables were assessed for interaction 
effect and significant interaction terms were described and utilized in the final 
model analysis.  
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Multiple logistic regression was then used to formulate the final model of 
those with late-stage disease. The model was first run with all covariates and 
then variables were removed using backward elimination to find the model of 
best fit. All reported P-values are two-tailed with statistical significance set at an 
alpha level of 0.05. All analyses were conducted using SPSS version 23. 161 
 
Results 
 
The demographic characteristics of the study population: all cases, early-
stage and late-stage disease are described in table 3.1. There are 10,109 cases 
reported with 13.6% late-stage. Comparing early and late-stage disease groups, 
both have similar distribution of age with the mean age of all cases at 56.9 years 
with a standard deviation of 16.2 and a range of 18-102 years. The majority of 
cases occur in males with 63% of late cases found in males.  Almost half of all 
cases, early and late-stage occur in married individuals.  
The majority of all cases and early-stage cases are on the trunk and 
shoulders, hips, or limbs. Whereas almost a quarter of late-stage cases are 
defined as overlapping or not otherwise specified (NOS). Almost half of all cases, 
early and late-stage are reported in those with private health insurance.  Late-
stage cases are more commonly uninsured or insured with Medicaid or Medicare 
compared to early-stage lesions. Those who reside in urban areas and non-
Appalachian counties report the majority of all cases, early and late-stage.  The 
mean percentage of those living below the poverty level by county is 15.5% with 
a range of 4.1- 45.0%.  The mean percentage of those with a high school 
education level by county is 74.5%, with a range of 49 - 87%.  
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 The entire state of Kentucky has 9,109 physicians with a range of 0 - 56.5 
per 10,000 population in each county. There are 1,361 family practice physicians 
with a range of 0 - 7.7 per 10,000 population in each county and 121 
dermatologists with a range of 0 - 0.93 per 10,000 population in each county with 
the majority of counties without a dermatologist. There is a mean 20.9 all-
physicians per 10,000 population for late-stage cases, compared to the early 
cases at 21.7. The number of family physicians and dermatologists was similar 
for early and late-stage groups.  
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Table 3.1: Characteristics of Melanoma Cases by Disease Stage in 
Kentucky from 1995-2013 
 
Covariates All Stages Early Stage Late Stage 
 n (%) n (%) n (%) 
Cases 10,109 8,735 (86.4) 1,374 (13.6) 
Age 
18-34  
35-64  
>64  
 
957 (9.5) 
5,732 (56.7) 
3,420 (33.8) 
 
836 (9.6) 
4,951 (56.7) 
2,948 (33.7) 
 
121 (8.8) 
781 (56.8) 
472 (34.4) 
Gender 
Male 
Female 
 
5,433 (53.7) 
4,676 (46.3) 
 
4,567 (52.3) 
4,168 (47.7) 
 
866 (63.0) 
508 (37.0) 
Marital Status 
Married/Partner 
Single 
Widowed 
Separated/Divorced 
Unknown 
 
4,450 (44) 
723 (7.2) 
578 (5.7) 
612 (6.1) 
3746 (37.1) 
 
3,803 (43.5) 
568 (6.5) 
495 (5.7) 
463 (5.3) 
3,406 (39)  
 
647 (47.1) 
155 (11.3) 
117 (8.5) 
115 (8.4) 
340 (24.7) 
Year Diagnosed 
1995-1998 
1999-2002 
2003-2006 
2007-2009 
2010-2013 
 
1,343 (13.3) 
1,638 (16.2) 
2,094 (20.7) 
1,998 (19.8) 
3,036 (30.0) 
 
1,165 (13.3) 
1,324 (15.2) 
1,845 (21.1) 
1,745 (20.0) 
2,656 (30.4) 
 
178 (13.0) 
314 (22.9) 
249 (18.1) 
253 (18.4) 
380 (27.7) 
Anatomic Site 
Face, Head, Neck 
Trunk 
Limbs, Shoulder, Hips 
Overlapping, NOS 
 
1,898 (18.8) 
3,542 (35) 
4,328 (42.8) 
341 (3.4) 
 
1,666 (19.1) 
3,157 (36.1) 
3,886 (44.5) 
26 (0.3) 
 
232 (16.9) 
385 (28) 
442 (32.2) 
315 (22.9) 
Insurance 
Private insurance 
Uninsured 
Medicaid 
Medicare 
Unknown 
 
4,820 (47.7) 
364 (3.6) 
334 (3.3) 
2,997 (29.6) 
1,594 (15.8) 
 
4,175 (47.8) 
260 (3.0) 
233 (2.7) 
2,506 (28.7) 
1,561 (17.9) 
 
645 (46.9) 
104 (7.6) 
101 (7.4) 
491 (35.7) 
33 (2.4) 
Geography 
Urban 
Rural 
 
5,504 (54.4) 
4,605 (45.6) 
 
4,776 (54.7) 
3,959 (45.3) 
 
728 (53.0) 
646 (47.0) 
Geography 
Non-Appalachian 
Appalachian 
 
7,326 (72.5) 
2,783 (27.5) 
 
6,359 (72.8) 
2,376 (27.2) 
 
967 (70.4) 
407 (29.6) 
 Mean (SD) Mean (SD) Mean (SD) 
Poverty level 15.5% (6.6%) 15.4% (6.5%) 16.0% (7.1%) 
Education level 74.5% (9.2%) 74.6% (9.2%) 73.8% (9.5%) 
All MD per 10,000  21.6 (14.7) 21.7 (14.8) 20.9 (14.3) 
FP MD per 10,000 3.03 (1.32) 3.03 (1.32) 3.00 (1.33) 
Derm per 10,000 0.29 (0.30) 0.29 (0.30) 0.27 (0.30) 
MD, medical doctor, includes all physicians including doctors of osteopathic medicine 
FP, family practice; Derm, dermatologists 
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Figure 3.1 demonstrates the dramatic increase in early-stage melanoma 
between 1995 and 2013. The number of early-stage melanoma cases has 
steadily increased with a large increase in cases from 2003 to 2006 and the 
largest number of cases reported from 2010 to 2013. Further analysis of year 
groups 1995 to 2002 and 2003 to 2013 did not reveal a significant difference 
among these groups to explain the rise in early-stage cases. The number of late-
stage melanomas has also steadily increased with a bump in the number of 
cases reported in 1999 to 2002 and the largest number of cases reported from 
2010 to 2013.  Of the 8,735 early-stage cases, 23.9% of the male and 21.6% of 
the females died. Of the 1,374 late-stage cases, 68.1% of the male and 61.8% of 
the females died.  
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Figure 3.1: Early and Late-Stage Melanoma by Year of Diagnosis in 
Kentucky from 1995-2013 
 
 
 
 
 
The unadjusted odds ratios for late-stage melanoma are presented in 
table 3.2. Surprisingly, both of the geographic region variables and age are not 
significantly associated with late-stage melanoma lesions. Further analysis of 
each of these variables with stratification by year of diagnosis and pair-wise 
comparison again did not reveal an association. Females have a 36% (CI 0.57-
0.72) decreased odds of late-stage melanoma compared to males. Meanwhile, 
being single has a 60% (CI 1.32-1.95) increased odds of late-stage melanoma 
compared to being married, whereas being separated or divorced has a 39% (CI 
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1.12-1.73) increased odds and being widowed has a 46% (1.17-1.82) increased 
odds. The year of diagnosis is significant only for the years of 1999-2002 having 
a 55% (1.27-1.90) increased odds of late-stage melanoma compared to 1995-
1998. Interestingly, pair-wise comparison between year groups revealed no 
significant association between groups except for increased odds of late-stage 
disease for 1999-2002 compared to all other year groups. Interestingly, late-
stage melanoma has a 18% (0.69-0.97) decreased odds for limbs, shoulder and 
hips lesions while there is a 87 times increased odds with overlapping or NOS 
lesions. Those people who are uninsured have a 2.59 (CI 2.03-3.30) times higher 
odds of late-stage melanoma compared to those who have private insurance 
while those with Medicaid have a 2.81 (CI 2.19-3.60) higher odds and those with 
Medicare have a 29% (CI 1.12-1.44) higher odds.  
Poverty level, education level and density of dermatologists were each 
found to be significant in the univariate analysis. So, if a county had a 10% 
increase in percentage of the county in poverty there would be a 10% increased 
odds of late-stage melanoma. At the same time, if a county had a 10% decrease 
in percentage of the county that graduated from high school there would be a 
10% increased odds of late-stage melanoma. While only 23 counties out of 120 
have a dermatologist at all, we found that if a county added one dermatologist 
the odds of reporting a late-stage melanoma decreased by 23% (CI 0.64-0.93).  
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Table 3.2: Unadjusted Odds Ratio of Late-Stage Melanoma in Kentucky 
from 1995-2013.  
 
Covariates Late-Stage Late-Stage 
 OR (95% CI) P value 
Age 
18-34  
35-64  
>64  
 
Referent 
1.09 (0.89-1.34) 
1.11 (0.89-1.37) 
 
 
0.411 
0.355 
Gender 
Male 
Female 
 
Referent 
0.64 (0.57-0.72) 
 
 
<0.005 
Marital Status 
Married/ Partner 
Single 
Separated/Divorced 
Widowed 
Unknown 
 
Referent 
1.60 (1.32-1.95) 
1.39 (1.12-1.73) 
1.46 (1.17-1.82) 
0.59 (0.51-0.67) 
 
 
<0.005 
0.001 
0.003 
<0.005 
Year Diagnosed 
1995-1998 
1999-2002 
2003-2006 
2007-2009 
2010-2013 
 
Referent 
1.55 (1.27-1.90) 
0.88 (0.72-1.09) 
0.95 (0.77-1.17) 
0.94 (0.77-1.13) 
 
 
<0.005 
0.237 
0.617 
0.500 
Anatomic Site 
Face, Head, Neck 
Trunk 
Limbs, Shoulder, Hips 
Overlapping, NOS  
 
Referent 
0.88 (0.74-1.04) 
0.82 (0.69-0.97) 
87.00 (57.00-132.79) 
 
 
0.134 
0.019 
<0.005 
Insurance 
Private insurance 
Uninsured 
Medicaid 
Medicare 
Unknown 
 
Referent 
2.59 (2.03-3.30) 
2.81 (2.19-3.60) 
1.29 (1.12-1.44) 
0.14 (0.10-0.20) 
 
 
<0.005 
<0.005 
<0.005 
<0.005 
Geography 
Urban 
Rural 
 
Referent 
1.07 (0.96-1.2) 
 
 
0.242 
Geography 
Non-Appalachian 
Appalachian 
 
Referent 
1.13 (0.99-1.28) 
 
 
0.062 
Poverty level 1.01 (1.01-1.02) 0.002 
Education level 0.99 (0.98-1.00) 0.007 
All physicians 1.0 (0.99-1.0) 0.075 
Family practice  0.99 (0.95-1.03) 0.583 
Dermatologist 0.77 (0.64-0.93) 0.007 
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Analysis for interaction effect revealed interaction between age and 
gender and insurance and gender to be significant, refer to table 3.3. Females 
35-64 years old and greater than 64 have 40% (CI 0.44-0.79) and 32% (CI 0.57-
0.81) decreased odds of late-stage melanoma compared to females 18-34 years 
old. At the same time, males 35-64 years old have a 42% (CI 1.05-1.93) 
increased odds compared to females 18-34 years old. Also, compared to insured 
females, uninsured females, those on Medicare or with unknown insurance are 
all at increased odds of late-stage disease but those on Medicaid are at the 
highest risk with an over 11 (CI 6.56-19.93) fold odds. Meanwhile, the men 
uninsured, on Medicaid, Medicare or unknown insurance are at even higher odds 
of late-stage disease compared to insured females. Particularly, men on 
Medicaid are at a 20 (CI 12.26-35.38) fold increased odds and men on Medicare 
are at an almost 36 (CI 20.88-61.40) fold increased odds of late-stage 
melanoma.   
 
Table 3.3: Interaction between Age and Gender and Insurance Status and 
Gender for Late-Stage Melanoma in Kentucky from 1995-2013. 
 
 Female Male 
 OR (95% CI) P value 
Age   
18-34  
35-64  
>64 
 
Referent 
0.60 (0.44-0.79)* 
0.68 (0.57-0.81)* 
 
0.84 (0.68-1.02) 
1.42 (1.05-1.93)* 
1.15 (0.98-1.34) 
Insurance 
Private insurance 
Uninsured 
Medicaid 
Medicare 
Unknown 
 
Referent 
4.61 (2.93-7.24)* 
11.44 (6.56-19.93)* 
7.61 (4.25-13.64)* 
6.80 (4.23-10.78)* 
 
0.64 (0.31-1.31) 
7.57 (4.84-11.82)* 
20.82 (12.26-35.38)* 
35.80 (20.88-61.40)* 
8.35 (5.32-13.09)* 
* Indicates P value less than 0.05 
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The final model is displayed in table 3.4 and demonstrates that marital 
status, year diagnosed, anatomic site and insurance*gender are associated with 
late-stage melanoma. The final model explains 14.4% (Cox and Snell R square) 
and 26.3% (Nagelkerke R squared) of the variance in late-stage of diagnosis. A 
Hosmer-Lemeshow goodness of fit test was conducted and gave no indication of 
poor model fit at the 0.05 level (p value 0.081).  
In the final model single people have a 39% (CI 1.11-1.75) increased odds 
of late-stage disease, widowed have a 44% (CI 1.11-1.89) increased odds and 
divorced people have a 36% (CI 1.06-1.75) increased odds compared to those 
who are married. As the incidence rate of melanoma increases from 1995 to 
2013 the odds of late-stage diagnosis is significantly less from 2003 to 2013. 
Having a lesion that is overlapping or NOS increases the odds of late-stage 
disease 82 (CI 53.84-127.84) fold. Meanwhile, compared to privately insured 
females, being an uninsured female increases the odds of late-stage disease 
over 3 (CI 1.93-5.51) fold and being a female on Medicaid increased the odds 
over 7 (CI 4.08-14.31) fold. At the same time, men are at greater odds of late-
stage melanoma compared to insured females with uninsured men at almost a 5 
(CI 2.83-8.00) fold odds, men on Medicaid with almost a 12 (CI 6.36-21.59) fold 
odds and men on Medicare with a 19 (CI 10.35-35.63) times higher odds of late-
stage disease compared to insured females. While the univariate analysis 
showed a significant impact of poverty, education and physician density on late-
stage disease the adjusted regression did not show these outcome variables of 
interest to be significant.   
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Table 3.4: Final Model of Adjusted Odds Ratio of Late-Stage Melanoma in 
Kentucky from 1995-2013. 
 
 
Covariates Late-Stage Late-Stage 
 OR (95% CI) P value 
Marital Status 
Married/Partner 
Single 
Widowed 
Separated/Divorced 
Unknown 
 
Referent 
1.39 (1.11-1.75) 
1.44 (1.11-1.89) 
1.36 (1.06-1.75) 
0.73 (0.58-0.93) 
 
 
0.005 
0.007 
0.015 
0.008 
Year Diagnosed 
1995-1998 
1999-2002 
2003-2006 
2007-2009 
2010-2013 
 
Referent 
1.30 (1.00-1.68) 
0.66 (0.48-0.90) 
0.69 (0.50-0.94) 
0.69 (0.51-0.93) 
 
 
0.051 
0.009 
0.019 
0.019 
Anatomic Site 
Face, Head, Neck 
Trunk 
Limbs, Shoulder, Hips 
Overlapping, NOS  
 
Referent 
0.92 (0.76-1.10) 
0.90 (0.75-1.07) 
82.90 (53.84-127.84) 
 
 
0.343 
0.231 
<0.005 
Insurance*Gender 
Female Private insurance 
Female Uninsured 
Female Medicaid 
Female Medicare 
Female Unknown 
Male Private insurance 
Male Uninsured 
Male Medicaid 
Male Medicare 
Male Unknown 
 
Referent 
3.26 (1.93-5.51) 
7.64 (4.08-14.31) 
4.66 (2.40-9.06) 
4.08 (2.38-7.00) 
0.67 (0.31-1.44) 
4.76 (2.83- 8.00) 
11.72 (6.36- 21.59) 
19.2 (10.35-35.63) 
5.03 (2.98-8.48) 
 
 
<0.005 
<0.005 
<0.005 
<0.005 
0.302 
<0.005 
<0.005 
<0.005 
<0.005 
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Discussion 
 
Kentucky is a rural state with high poverty, low high school education 
levels and low physician density that has high melanoma incidence and mortality 
rates.  Despite these factors this analysis did not find strong evidence to 
conclude that the stage of melanoma diagnosis is impacted by poverty, 
education or physician density.  Instead, this analysis supports previous research 
that demonstrates that gender, marital status and health insurance status affect 
stage of diagnosis--indicating the population at highest risk for late-stage 
melanoma in Kentucky is unmarried males without insurance, on Medicaid or 
Medicare. 65,123,125  
This study found that Kentucky mirrors the US with 86.4% of lesions 
diagnosed as early-stage and the incidence rate rising dramatically over the last 
few decades. 7 The upswing in early-stage cases in Kentucky begins in 2003 with 
no obvious explanation. In 2002 the AJCC did publish an updated staging 
manual that included tumor thickness and ulceration in the T category. 17 It is 
possible that this change in staging could increase the number of lesion 
considered early-stage but would not account for the continued surge still seen 
today. Instead, this continued increase is most likely attributed to our aging 
population, increased screening, increased recreational UV exposure and 
increased tanning bed use. 2,6,14,17,59,62 
As expected, the majority of cases were male but the average overall age 
was younger, 56.9 years, than the national average of 63 years. 7 Interestingly, 
the location of the lesion remained important as lesions on the limbs, shoulders 
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and hips had a slight increase in late-stage disease compared to early-stage in 
the univariate analysis, but astonishingly in the final model the overlapping lesion 
or lesion NOS had an 83 times higher odds of late-stage disease. The influence 
of geographic region such as, rural or Appalachia residence was not associated 
with a greater odds of being a late-stage case. Yet, having a spouse or partner 
was clearly protective from being diagnosed with late-stage melanoma. This 
supports previous research by Mandala et al that marriage is protective against 
later stage melanoma with those who are widowed at particularly increased 
risk.123 
In a nation that does not provide affordable health care without insurance 
it is not unexpected that being uninsured or having Medicaid increases the odds 
of late-stage melanoma. The analysis of interaction emphasizes the importance 
and complexity of insurance by noting that females and males on Medicaid are at 
increased odds of late-stage diagnosis. While at the same time, males with 
Medicare are at dramatically increased odds of late-stage disease compared to 
females with private insurance.  
Education and poverty level by county was utilized to measure the effect 
of SES on late-stage melanoma.  Increased poverty and decreased education 
was noted to be associated with late-stage disease in the univariate analysis but 
this paper did not find an association in the final model when controlling for all 
other variables. Physician density by county was significant for dermatologists in 
the univariate analysis but not in the final model.    
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This study has several important limitations. First, poverty and education 
were used as surrogates for socioeconomic status and were measured at the 
county level, not the individual level. Yet, the use of aggregate measures of 
socioeconomic status has been validated by other studies. 29-31 Secondly, 
physician density can only be considered an aggregate of patients’ use of 
medical services. The actual use of physician services by these patients may not 
be reflective of the physician density. Additionally, this study did not account for 
other medical providers including physician assistants and nurse practitioners. 
The analysis of poverty level, education level and physician density by county in 
a state with 120 counties may have been a too finite breakdown of the data. 
Further research should consider analysis by larger geographic regions. Lastly, 
this study was restricted to the state of Kentucky, which may not be 
representative of other parts of the country.  
As the rate of melanoma continues to increase, this study shows that 
Kentucky needs to focus preventative health measures towards unmarried men 
who do not have private insurance, especially those with Medicare. Since this 
analysis did not demonstrate any influence of poverty or education at the county 
level, further research needs to be conducted with individual level data. 
Additionally, the effect of health insurance status on melanoma disease stage 
seen in this analysis lends itself to further investigation. Of interest would be the 
effect of the recent expanded health insurance access through the Affordable 
Care Act that has provided over 500,000 uninsured Kentucky residents with 
coverage. 162 
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Kentucky is a rural state with high poverty, lower than average education 
levels and low physician density but it appears that these factors have not 
impacted melanoma stage of diagnosis.  Instead this study supports previous 
research that indicates that public health measures should focus on unmarried 
men who are uninsured or on Medicaid or Medicare. 21,74,125    
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Chapter IV 
 
Individual and Social Factors Associated with Non-standard Surgical 
Treatment For Early-stage Melanoma in Kentucky 
 
Introduction 
 
Over the last three decades the incidence of melanoma has doubled in the 
United States (US) while the mortality rate has remained stable. 3 The prognosis 
for melanoma is excellent with a 98% 5-year survival rate for early-stage 
disease.7 Consequently, early diagnosis and complete removal of the lesion is 
paramount as local recurrence is associated with the development of systemic 
metastasis and a poor prognosis of less than a 5% chance of survival at 10 
years. 131 
As the incidence of melanoma increases the number of clinicians 
providing treatment increases which makes the need for treatment guidelines 
paramount. 22,128 The National Comprehensive Cancer Network (NCCN) provides 
evidence-based consensus-driven guidelines by cancer type to help guide 
clinicians. 163 The NCCN melanoma treatment guidelines state that the primary 
and potentially curative treatment for early-stage melanoma is wide local excision 
to completely remove the lesion with clear margins. 47 Clear margins are defined 
as the edge or border of the tissue that is removed around a cancer that is found 
to be without cancer cells by the pathologist. 164 At least 1 cm and no more than 
2 cm of clear surgical margins is recommended. 47,51,130 No residual tumor is 
considered the standard of care treatment that should be provided to all patients 
unless not appropriate based on their unique medical situation. 47  
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Despite the specific treatment guidelines from the NCCN, evidence 
suggests that melanoma surgical guidelines are followed approximately half of 
the time. 28 The effect of this non-standard treatment is unclear because the 
association between inadequate margins and mortality has not been confirmed 
but continued morbidity can be inferred because several studies have 
established that inadequate surgical margins are correlated with local 
recurrence.51,53,54,58,134, Therefore, the current belief is that as inadequate 
margins increase the risk of local reoccurrence it may also be associated with 
increased mortality. 53-55  
Although each medical situation varies, this level of variation in adherence 
to medical guidelines for melanoma treatment may be a symptom of inequity in 
health care delivery. While there are many papers on the risk factors that 
influence melanoma incidence and mortality the literature on surgical treatment is 
anemic. At this time, the research indicates that those less likely to be provided 
the standard of care surgical treatment have an early-stage lesion, are older, 
minority race, not married, resided in rural areas and the lesion is on their head 
or neck. 28,53,54,85,123,132,143,145-148  
A study by Al-Quaryshi et al also noted that patients with low annual 
incomes or on Medicaid were more likely to be treated by a low-volume 
surgeon.144 At the same time these low-income patients were more likely to be 
treated in a non-teaching, rural or low-volume hospital. 144 Additionally, an 
analysis of disparities in cancer care in West Virginia noted that residing in rural 
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Appalachia itself has been associated with later stage cancer diagnoses, 
variance in treatment and survival. 165  
Differences in melanoma treatment have also been associated with 
physician specialty, where they work in the healthcare system and their practice 
patterns. 85,149 Rivard et al found that when comparing the referral cancer center 
to outside centers that the referral cancer center more commonly followed 
surgical guidelines for sentinel lymph node biopsy but less commonly for wide 
surgical excision. 149 While melanoma surgical treatment adherence has not 
been linked to physician density, access to family practice physicians and 
dermatologists is associated with earlier stage diagnosis while access to 
dermatologists is associated with lower mortality. 22,128  
Kentucky is an excellent population to study adherence of melanoma 
surgical treatment guidelines because of the high rate of melanoma in the state 
with a majority white population. Also, the high poverty rate, wide range in 
education levels, low physician density, rural and Appalachian geography makes 
this an ideal place to investigate the effect of these social determinants of health 
on early-stage melanoma treatment.  
The purpose of this paper is to assess for any associations between 
individual and social factors on treatment provided to early-stage melanoma in 
white non-Hispanic Kentuckians from 1995 to 2013. We hypothesize that non-
standard treatment more frequently occurs in rural and Appalachian regions and 
geographic areas with lower physician density and lower socioeconomic status 
(SES) as indicated by an increase in poverty level and decrease in education 
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level. This study intends to lend insight into the factors associated with non-
standard surgical treatment for early-stage melanoma in Kentucky, which in turn 
could provide an avenue for public health intervention.  
 
Methods 
Study population and data resources 
The Kentucky Cancer Registry (KCR) provided data on individual level 
variables while the United States Census Bureau and the Kentucky Department 
of Public Health delivered the community level variables. Early-stage melanoma 
cases from non-Hispanic whites, 18 years or older from 1995 to 2013 were 
gathered; insitu lesions and non-primary tumors were excluded. Early-stage was 
defined as stage I and stage II. Due to minimal cases in other race groups only 
non-Hispanic whites were included. Cases without treatment data were excluded. 
This provided data on 8,532 cases with individual data on age, gender, marital 
status, year of diagnosis, anatomic site of lesion, health insurance status, and 
geographic region of rural/urban and Appalachian/non-Appalachian. 
The percentage of each county with high school education and 
percentage below the poverty level was collected from the 2000 United States 
Census Bureau. 8,11 Meanwhile, the 2006 physician licensure data with the 
number of all-physicians, family practice physicians and dermatologists in each 
county was provided by the Kentucky Department of Public Health. 12 Physician 
density was calculated with the number of all-physicians, family physicians and 
dermatologists, per 10,000 population by county using the 2006 US Census 
Bureau intercensal population estimates. 159 
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Outcome and Independent Variables 
The outcome variable of interest--standard of care treatment--was formed 
into a dichotomous variable of yes/no. Standard of care treatment was defined as 
surgical margin code 0 which is no residual tumor with all margins grossly and 
microscopically negative. Non-standard of care treatment was defined as surgical 
margin codes 1-9 which includes residual tumor, microscopic residual tumor, 
macroscopic residual tumor, margins not evaluable, no surgical removal of the 
primary site and unknown. 166  
The independent variables of interest are geographic region, poverty level, 
education level and physician density. Geographic region is defined with two 
variables: rural/urban and Appalachian/non-Appalachian. Urban is defined as 
Beale codes 1 through 3 while rural is defined as Beale codes 4 through 9. Non-
Appalachian is defined by counties defined as non-Appalachian. 160 Poverty level 
was categorized into three groups based upon the mean of 15.5% with high as 
greater than 20% of population in poverty, intermediate as 10 to 20% of 
population in poverty and low as less than 10% of population in poverty. 
Education level was categorized into three groups with less than 70% with high 
school education level defined as low education, 70 to 80% as intermediate 
education, and greater than 80% as high education.  
Physician density per 10,000 population per county was defined by the 
following three categories: all physicians, family practice physicians and 
dermatologists. All physicians was applied as melanoma is diagnosed and 
treated by many types of physicians not only family practice physicians and 
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dermatologists. All Kentucky physicians were categorized into three groups 
based upon a mean of 21.68 physicians per 10,000 population with high 
indicating greater than 25 physicians, intermediate indicating counties with 12 to 
25 physicians and low for counties with less than 12 physicians. Family practice 
physicians were categorized into three groups as well based on a mean of 3.03 
physicians per 10,000 population with high indicating greater than 3.10 
physicians, intermediate indicating 2.6 to 3.09 physicians and low indicating less 
than 2.6 family practice physicians. Dermatologist were also categorized into 
three groups with a mean of 0.29 physicians with high indicating greater than 
0.65 dermatologists per 10,000 population, intermediate indicating 0.11 to 0.65 
dermatologists and low indicating less than 0.10 dermatologists.  
The year of diagnosis was categorized into five groups with 1995 to 1998, 
1999 to 2002, 2003 to 2006, 2007 to 2009 and 2010 to 2013.  Gender was 
categorized with male and female. Age was categorized into three groups with 65 
and older, 64 to 35 and 34 to 18 years.  Marital status is also categorical with 
married/partner, single, widow, separated/divorced and unknown. Health 
insurance status was categorized by primary payor type as private insurance, 
uninsured, Medicaid, Medicare and unknown. Anatomic site of the lesion was 
categorized based upon the area of the body.  
Statistical Analysis 
Descriptive statistics were used to describe the study population and the 
distribution of variables for all cases, standard treatment and non-standard 
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treatment. A graph exhibiting melanoma treatment non-adherence from 1995 to 
2013 was created.  
Logistic regression was used to assess the unadjusted associations 
between each covariate and non-standard treatment. Covariates include age at 
diagnosis, gender, marital status, year diagnosed, anatomical site of lesion, 
health insurance status, urban/rural, non-Appalachian/Appalachian, poverty level, 
education level and physician population ratio for all-physicians, family practice 
physicians and dermatologists. The resultant estimated odds ratios (OR) and 
95% confidence interval were described. Each significant variable was assessed 
for interaction and significant interaction terms were described.  These significant 
interaction terms were then utilized in the final model.  
Multiple logistic regression was used to formulate the final model of the 
non-standard treatment group. The model was first run with all covariates then 
variables were removed using backward elimination to find the model of best fit.  
All reported P values are two-tailed. Statistical significance was set at an alpha 
level of .05. All analyses were conducted using SPSS version 23. 161 
 
Results 
 
 Of the 8,532 cases, 5,099 (59.8%) were provided the recommended 
standard of care treatment for their early-stage melanoma lesion, leaving 3,433 
cases with non-compliant treatment. Refer to table 4.1. The mean age of all 
early-stage cases is 56.8 years with a standard deviation of 16.2 years and range 
of 18 to 102 years old. For both the standard treatment and non-standard 
treatment groups the majority of cases were 35 to 64 years old. While most of the 
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all cases group were married, 37.7% of cases had an unknown marital status. 
For the non-standard treatment group the percentage of unknown marital status 
rose to 44.1% while the married group comprised only 39.5% of cases. 
Exploratory analysis demonstrated that unknown marital status was not 
differentially distributed with other variables therefore; the variable of marital 
status was not evaluated further in the analysis.  
 The number of early-stage cases has increased by over two-fold from 
1995 to 2013. At the same time the percentage of cases that are non-standard 
treatment have significantly increased compared to the standard treatment 
group. The majority of lesions in the standard and non-standard treatment groups 
were found on the limbs, shoulders and hips. In the standard treatment group 
57.4% of cases had private insurance while in the non-standard treatment group 
only 35.9% had private insurance. The standard and non-standard treatment 
groups are similar with the bulk residing in urban and non-Appalachian regions.   
The mean percentage of poverty level by county for all cases is 15.5% 
with a standard deviation of 6.5% and range of 4.1% to 45.4%. The standard 
treatment and non-standard treatment groups are similar in poverty levels with 
the non-standard group having a slightly higher percentage of cases in the high 
and low poverty levels. The mean percentage of high school education level by 
county for all cases is 74.5% with a standard deviation of 9.2% and range of 
49.2% to 86.5%. All three groups were similar with each group having greater 
than 40% of cases at a high level of education. 
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The state of Kentucky has 9,109 physicians, 1,361 family practice 
physicians and 121 dermatologists. There is a wide range of all physicians with 
zero to 56.5 per 10,000 population per county. Comparing the standard and non-
standard treatment groups the physician density is similar. Meanwhile, the 
number of family practice physicians per 10,000 population per county has a 
limited range of 0 to 7.7 but significant variation between the standard and non-
standard treatment groups. With the non-standard treatment group having 37.8% 
of cases from counties with high family practice physician density.  While the 
majority of counties do not have a dermatologist, the range of dermatologists per 
10,000 population is only 0 to 0.93. Comparing treatment groups there are less 
non-standard treatment cases coming from counties with high dermatologist 
density.  
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Table 4.1, Characteristics of Melanoma Cases by Treatment in Kentucky 
from 1995-2013 
 
Covariates All Cases Standard 
Treatment 
Non-Standard 
Treatment 
 n (%) n (%) n (%) 
Cases 8,532 (100.0) 5,099 (59.8) 3,433 (40.2) 
Age 
18-34  
35-64  
>65  
 
816 (9.6) 
4,849 (56.8) 
2,867 (33.6) 
 
517 (10.1) 
2,993 (58.7) 
1,589 (31.2) 
 
299 (8.7) 
1,856 (54.1) 
1,278 (37.2) 
Gender 
Male 
Female 
 
4,464 (52.3) 
4,068 (47.7) 
 
2,634 (51.7) 
2,465 (48.3) 
 
1,830 (53.3) 
1,603 (46.7) 
Marital Status 
Married 
Single 
Widowed 
Separated/Divorced 
Unknown 
 
3,792 (44.4) 
568 (6.7) 
458 (5.4) 
495 (5.8) 
3,219 (37.7) 
 
2,432 (47.7) 
354 (6.9) 
278 (5.5) 
331 (6.5) 
1,704 (33.4)  
 
1,360 (39.6) 
214 (6.2) 
180 (5.2) 
164 (4.8) 
1,515 (44.1) 
Year Diagnosed 
1995-1998 
1999-2002 
2003-2006 
2007-2009 
2010-2013 
 
1,155 (13.5) 
1,319 (15.5) 
1,839 (21.6) 
1,711 (20.1) 
2,508 (29.4) 
 
1,009 (19.8) 
1,220 (23.9) 
1,117 (21.9) 
814 (16) 
939 (18.4) 
 
146 (4.3) 
99 (2.9) 
722 (21) 
897 (26.1) 
1,569 (45.7) 
Anatomic Site 
Face, Head, Neck 
Trunk 
Limbs, Shoulder, Hips 
Overlapping, NOS 
 
1,620 (19.0) 
3,074 (36.0) 
3,815 (44.7) 
23 (0.3) 
 
898 (17.6) 
1,848 (36.2) 
2,340 (45.9) 
13 (0.3) 
 
722 (21) 
1,226 (35.7) 
1,475 (43) 
10 (0.3) 
Insurance 
Private insurance 
Uninsured 
Medicaid 
Medicare 
Unknown 
 
4,157 (48.7) 
260 (3.0) 
233 (2.7) 
2,492 (29.2) 
1,390 (16.3) 
 
2,926 (57.4) 
181 (3.5) 
163 (3.2) 
1,679 (32.9) 
150 (2.9) 
 
1,231 (35.9) 
79 (2.3) 
70 (2.0) 
813 (23.7) 
1,240 (36.1) 
Geography 
Urban 
Rural 
 
4,640 (54.4) 
3,892 (45.6) 
 
2,775 (54.4) 
2,324 (45.6) 
 
1,865 (54.3) 
1,568 (45.7) 
Geography 
Non-Appalachian 
Appalachian 
 
6,189 (72.5) 
2,343 (27.5) 
 
3,784 (74.2) 
1,315 (25.8) 
 
2,405 (70.1) 
1,028 (29.9) 
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Table 4.1, continued 
 
Covariates All Cases Standard 
Treatment 
Non-Standard 
Treatment 
 n (%) n (%) n (%) 
Poverty level 
Low  
Intermediate 
High 
 
1,145 (13.4) 
5,804 (68.0) 
1,583 (18.6) 
 
582 (11.4) 
3,590 (70.4) 
927 (18.2) 
 
563 (16.4) 
2,214 (64.5) 
656 (19.1) 
Education level 
High  
Intermediate 
Low 
 
3,608 (42.3) 
2,436 (28.6) 
2,488 (29.2) 
 
2,167 (42.5) 
1,470 (28.8) 
1,462 (28.7) 
 
1,441 (42.0) 
966 (28.1) 
1.026 (29.9) 
All physicians 
High 
Intermediate 
Low 
 
3,092 (36.2) 
2,696 (31.6) 
2,744 (32.2) 
 
1,870 (36.7) 
1,579 (31.0) 
1,650 (32.4) 
 
1,222 (35.6) 
1,117 (32.5) 
1,094 (31.9) 
Family practice physicians 
High 
Intermediate 
Low 
 
2,810 (32.9) 
2,860 (33.5) 
2,862 (33.5) 
 
1,511 (29.6) 
1,835 (36.0) 
1,753 (34.4) 
 
1,299 (37.8) 
1,025 (29.9) 
1,109 (32.3) 
Dermatologists 
High 
Intermediate 
Low 
 
2,230 (26.1) 
2,543 (29.8) 
3,759 (44.1) 
 
1,367 (26.8) 
1,465 (28.7) 
2,267 (44.5) 
 
863 (25.1) 
1,078 (31.4) 
1,492 (43.5) 
 
 
Figure 4.1 demonstrates the dramatic increase in the number of early-
stage melanoma lesions provided non-standard treatment between 1995 and 
2013. From 1995 to 2002 less than 50 cases per year received non-standard 
treatment. In 2003 the number rose to 60 then jumped to 247 in 2005 and by 
2012 over 400 cases received non-standard treatment.  
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Figure 4.1, Number of Early-Stage Cases with Non-Standard Treatment by 
Year in Kentucky from 1995-2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 shows the proportion of early-stage lesions from 1995 to 2013 
that received non-standard treatment. From 1995 to 2003 less than 20% of cases 
received non-standard treatment then interestingly, this proportion increased 
dramatically with 48% in 2005 and 67% in 2013.  
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Figure 4.2, Proportion of Early-Stage Cases with Non-Standard Treatment 
by Year in Kentucky from 1995-2013 
 
 
 
 
The unadjusted odds ratios for non-standard treatment compared to 
standard treatment of early-stage melanoma are presented in table 4.2. 
Interestingly, gender was not significant for non-standard treatment but age 
greater than 64 years was found to increase the odds of non-standard treatment 
by 39% (CI 1.16-1.63) compared to people aged 18 to 34. The year the 
melanoma lesion was diagnosed was significant for non-standard treatment with 
the odds increasing dramatically. The lesions diagnosed from 2010 to 2013 have 
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an 11.55 (9.54-13.98) times increased odds of non-standard treatment compared 
to the lesions diagnosed from 1995 to 1998.  
The anatomical site of a melanoma lesion also significantly effects the 
treatment with a lesion on the trunk, limbs, shoulders or hips with a decreased 
odds of non-standard treatment compared to the face, head or neck. Insurance 
status is not significant for non-standard treatment except for unknown insurance 
status, which has a 19.65 (16.38-23.57) times higher odds of non-standard 
treatment compared to private insurance.  
Remarkably, the unadjusted variables of urban vs. rural geography, 
education level and all physician density are not significantly associated with 
non-standard treatment. Now, residing in Appalachia does increase the odds of 
non-standard treatment by 23% (1.12-1.35) compared to residing in non-
Appalachia. Yet, surprisingly the odds of non-standard treatment is less likely in 
counties with higher poverty where they are 27% (0.63-0.85) less likely to receive 
non-standard treatment compared to those in low poverty level counties. Also 
interesting, the odds of non-standard treatment lessen as the family practice 
physician density decreases. At the same time, intermediate density for 
dermatologists has a 17% (1.04-1.31) increased odds of non-standard treatment 
compared to high-density counties.   
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Table 4.2, Unadjusted Odds Ratio of Melanoma Non-Standard Treatment 
cases in Kentucky, 1995-2013 
 
Covariates Non-Standard Treatment Non-Standard 
Treatment 
 OR (95% CI) P value 
Age 
18-34  
35-64  
>64  
 
Referent 
1.07 (0.92-1.25) 
1.39 (1.16-1.63) 
 
 
0.374 
<0.005 
Gender 
Male 
Female 
 
Referent 
0.94 (0.86-1.02) 
 
 
0.135 
Year Diagnosed 
1995-1998 
1999-2002 
2003-2006 
2007-2009 
2010-2013 
 
Referent 
0.56 (0.43-0.73) 
4.47 (3.67-5.44) 
7.62 (6.25-9.28) 
11.55 (9.54-13.98) 
 
 
<0.005 
<0.005 
<0.005 
<0.005 
Anatomic Site 
Face, Head, Neck 
Trunk 
Limbs, Shoulder, Hips 
Overlapping, NOS  
 
Referent 
0.83 (0.73-0.93) 
0.78 (0.70-0.88) 
0.96 (0.42-2.20) 
 
 
0.002 
<0.005 
0.917 
Insurance 
Private insurance 
Uninsured 
Medicaid 
Medicare 
Unknown 
 
Referent 
1.04 (0.79-1.36) 
1.02 (0.77-1.36) 
1.15 (1.03-1.28) 
19.65 (16.38-23.57) 
 
 
0.792 
0.889 
0.010 
<0.005 
Geography 
Urban 
Rural 
 
Referent 
1.00 (0.92-1.10) 
 
 
0.930 
Geography 
Non-Appalachian 
Appalachian 
 
Referent 
1.23 (1.12-1.35) 
 
 
<0.005 
Poverty level 
Low 
Intermediate 
High 
 
Referent 
0.64 (0.56-0.72) 
0.73 (0.63-0.85) 
 
 
<0.005 
<0.005 
Education level 
High 
Intermediate 
Low 
 
Referent 
0.99 (0.89-1.10) 
1.06 (0.95-1.17) 
 
 
0.825 
0.310 
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Table 4.2, continued 
 
Covariates Non-Standard Treatment Non-Standard 
Treatment 
 OR (95% CI) P value 
All physicians 
High  
Intermediate 
Low 
 
Referent 
1.08 (0.97-1.20) 
1.02 (0.91-1.13) 
 
 
0.140 
0.787 
Family practice physicians 
High  
Intermediate 
Low 
 
Referent 
0.65 (0.58-0.72) 
0.74 (0.66-0.82) 
 
 
<0.005 
<0.005 
Dermatologists 
High 
Intermediate 
Low 
 
Referent 
1.17 (1.04-1.31) 
1.04 (0.94-1.17) 
 
 
0.010 
0.447 
 
 
Table 4.3 shows the significant interaction terms of Appalachian 
geography and family practice physicians with poverty and family practice 
physicians. In counties with high density of family practice physicians, 
Appalachian areas have 36% (CI 0.55-0.75) lower odds of non-standard 
treatment compared to non-Appalachian areas. Whereas, when comparing non-
Appalachian areas low family practice physician density decreases the odds of 
non-standard treatment by 33% (CI 0.58-0.77) compared to high physician 
density counties. Notably, the interaction of poverty level and family practice 
physicians is significant for high-density family practice physicians where high 
poverty level counties have 147% (1.95-3.10) higher odds of non-standard 
treatment compared to low poverty level counties.  
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Table 4.3, Interaction between Geography and Family Practice Physicians 
and Poverty Level and Family Practice Physicians for Non-Standard 
Treatment in Kentucky from 1995-2013 
 
 FP High FP Intermediate FP Low 
 OR (95% CI) OR (95% CI) OR (95% CI) 
Geography 
Non-Appalachian 
Appalachian 
 
Referent 
0.64 (0.55-0.75)* 
 
1.13 (0.98-1.30)  
0.92 (0.77-1.10) 
 
0.67 (0.58-0.77)* 
0.92 (0.69-1.22) 
Poverty level 
Low 
Intermediate 
High 
 
Referent 
1.27 (1.06-1.52)* 
2.47 (1.95-3.10)* 
 
1.17 (0.86-1.58) 
0.83 (0.70-0.98)* 
1.25 (0.90-1.24) 
 
1.21 (0.98-1.51) 
0.92 (0.77-1.10) 
0.98 (0.77-1.24) 
* Indicates P value less than 0.05 
FP, family practice physician 
 
 
The final model was significant for the variables of interest: Appalachian 
geography, poverty level with family practice physician density and physician 
density. Refer to table 4.4. The final model explains 32.1% (Cox and Snell R 
square) and 43.4% (Nagelkerke R squared) of the variance in non-standard 
treatment.  
Early-stage melanoma lesions in those older than 64 years old are at a 
40% (CI 1.09-1.79) increased odds of non-standard treatment compared to those 
aged 18 to 34. Comparing the year diagnosed, from 2003 to 2013 the odds of 
non-standard treatment has increased dramatically. In 2003 to 2006 there was 
an almost 3 (CI 2.41-3.68) fold increase odds of non-standard therapy followed 
by a 5.77 (CI 4.67-7.12) fold increase odds of non-standard therapy in 2007 to 
2009 and by 2010 to 2013 there was an over 9 (CI 7.41-11.10) fold increase 
odds of non-standard therapy compared to the cases in 1995 to 1998.  
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 Lesions on the trunk, limbs, shoulders or hips have a 29% (CI 0.61-0.83) 
decreased odds of non-standard treatment compared to lesions on the face, 
head or neck. Insurance through Medicare is protective against non-standard 
treatment with a 24% (CI 0.63-0.91) decreased odds compared to private 
insurance while unknown insurance increases the odds over 15 (CI 12.50-18.79) 
fold. Demographics of the unknown insurance group are similar to all other cases 
except that 94% of unknown insurance group cases also had unknown marital 
status. 
 While controlling for all other variables in the model, Appalachian 
geography and physician density are significant for non-standard treatment. 
Residing in an Appalachian area increases the odds of non-standard treatment 2 
(CI 1.67-2.52) fold compared to residing in non-Appalachia. Residing in a county 
with low all-physician density increases the odds of non-standard treatment by 
34% (CI 1.05-1.72) but surprisingly low dermatologist density decreases the odds 
of non-standard treatment by 38% (CI 0.46-0.82).   
 The interaction between family practice physicians and poverty level 
remained significant in the final model highlighting the effect of high-density 
family practice physicians and poverty level. Counties with high and intermediate 
poverty and high family practice physician density have a 99% (CI 1.49-2.66) and 
72% (CI 1.16-2.53) increased odds of non-standard treatment compared to 
counties with low poverty and low family practice physician density.  
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Table 4.4, Final Model of Adjusted Odds Ratio of Melanoma Non-Standard 
Treatment cases in Kentucky, 1995-2013 
 
Covariates Non-Standard 
Treatment 
Non-Standard Treatment 
 OR (95% CI) P value 
Age 
18-34  
35-64  
>64  
 
Referent 
0.99 (0.83-1.21) 
1.40 (1.09-1.79) 
 
 
0.988 
0.009 
Year Diagnosed 
1995-1998 
1999-2002 
2003-2006 
2007-2009 
2010-2013 
 
Referent 
0.47 (0.36-0.63) 
2.98 (2.41-3.68) 
5.77 (4.67-7.12) 
9.07 (7.41-11.10) 
 
 
<0.005 
<0.005 
<0.005 
<0.005 
Anatomic Site 
Face, Head, Neck 
Trunk 
Limbs, Shoulder, Hips 
Overlapping, NOS  
 
Referent 
0.71 (0.61-0.83) 
0.71 (0.61-0.82) 
2.23 (0.88-6.08) 
 
 
<0.005 
<0.005 
0.090 
Insurance 
Private insurance 
Uninsured 
Medicaid 
Medicare 
Unknown 
 
Referent 
1.00 (0.74-1.36) 
0.86 (0.63-1.19) 
0.76 (0.63-0.91) 
15.33 (12.50-18.79) 
 
 
0.981 
0.360 
0.004 
<0.005 
Geography 
Non-Appalachian 
Appalachian 
 
Referent 
2.05 (1.67-2.52) 
 
 
<0.005 
All physicians 
High  
Intermediate 
Low 
 
Referent 
1.24 (0.99-1.54) 
1.34 (1.05-1.72) 
 
 
0.057 
0.017 
Dermatologists 
High 
Intermediate 
Low 
 
Referent 
0.58 (0.45-0.74) 
0.62 (0.46-0.82) 
 
 
<0.005 
<0.005 
Poverty level & FP physicians 
Low poverty, high density 
Low poverty, interm density 
Low poverty, low density 
Interm poverty, high density 
Interm poverty, interm density 
Interm poverty, low density 
High poverty, high density 
High poverty, interm density 
High poverty, low density 
 
Referent 
0.88 (0.61-1.28) 
0.99 (0.75-1.31) 
1.99 (1.49-2.66) 
1.11 (0.80-1.53) 
1.13 (0.85-1.49) 
1.72 (1.16-2.53) 
1.75 (1.11-2.76) 
1.25 (0.87-1.80) 
 
 
0.501 
0.945 
<0.005 
0.528 
0.404 
0.007 
0.015 
0.230 
FP, family practice physician 
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Discussion 
 This study found that 40% of early-stage melanoma lesions did not 
receive the standard of care surgical treatment, which mirrors the findings from 
previous studies. 28,85,142,143, While the number of melanoma cases has steadily 
increased over time, it is striking that the proportion of cases receiving non-
standard surgical treatment has dramatically increased overtime from a low of 
5.3% of cases in 2002 to a high of 67.3% of cases in 2013. This reinforced 
previous studies that have demonstrated a trend of decreasing compliance with 
wide local excision recommendations over the recent decades.130,142,143 The 
cause for this is unclear but this level on non-adherence to surgical guidelines 
may be a symptom of health disparities.  
As expected from previous research findings, the final model found 
increased odds of non-standard surgical treatment with older age and head or 
neck lesions. 53   Of interest, Medicare insurance was protective against non-
standard treatment while unknown insurance had a 15 fold increased odds. 
Improved collection of this variable is necessary to better understand this group.  
Interestingly, residing in Appalachian itself increased the odds of non-
standard treatment. This matches research that has found an increase in non-
standard cancer treatment in Appalachia for breast, lung and prostate cancer. 167-
169 For example, an analysis of lung cancer treatments in West Virginia noted 
non-compliant treatment in 46.5% of the cases.168  
The effect of physician density is fascinating as the final model indicates 
that low all-physician density increases the odds of non-standard therapy while 
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low dermatologist density decreases the odds. It must be noted that there are 
only 121 dermatologists in the state of Kentucky and only 21 out of 120 counties 
with a dermatologist. Therefore, dermatologist density must be further studied 
while the finding of increased odds for non-standard treatment associated with 
low all-physician density likely holds more weight. This supports the assertion 
that increasing access to health care through all physicians is critical in 
melanoma care.  
Earlier research has analyzed the effect of physician density on melanoma 
stage of diagnosis and mortality but this is the first to evaluate treatment 
adherence. 22 It must be pointed out that physician density in this study does not 
indicate where each person received treatment, as it is quite possible that 
patients left their county for melanoma treatment by a dermatologist or 
melanoma specialist. Also, physician density can only be considered an 
aggregate of patients’ use of medical services. The actual use of physician 
services by these patients may not be reflective of the physician density. 
Additionally, this analysis of physician density provides no insight into physician 
practice patterns or the utilization of non-physician clinicians including physician 
assistants and nurse practitioners.  
The interaction between poverty level and family practice physicians 
highlights the relationship between poverty and access to medical care. In 
counties of high family practice physician density if the county also had a high 
poverty level there was a significant increase in non-standard treatment 
compared to low poverty counties. This demonstrates that providing physicians 
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alone is not the answer to standard melanoma treatment but that poverty itself 
plays a role. This reinforces other papers that have demonstrated an association 
between socioeconomic status and melanoma incidence, mortality and 
chemotherapy treatment. 6,20,144 
Compliance with melanoma surgical guidelines is not expected to be 100% as 
the patient specific needs have priority over general guidelines. Reasons for 
noncompliance are many and it is likely that there are appropriate medical 
reasons for non-standard surgical treatment present in several of these cases. 
That being said, 40% noncompliance is high and while physician and patient 
preference during treatment discussions is difficult to study this study lends some 
insight into which patients may be vulnerable. This analysis defines the 
vulnerable patient as one who is older than 65 years with a head or neck lesion, 
and with unknown insurance status. Additionally, those residing in Appalachia, a 
county with low all-physician density or a county with high or intermediate poverty 
with high family practice density and high dermatologist density are susceptible.  
This paper demonstrates that the incidence of non-standard treatment is 
increasing in Kentucky and it is not clear who is providing this treatment.  It is 
known that as the incidence of melanoma increases, the care for these deadly 
lesions spreads beyond dermatologists to clinicians who do not care for a large 
number of melanoma patients, attend multidisciplinary conferences or receive 
relevant continued medical education. 170 Previous studies have noted that 
increased compliance with surgical guidelines is associated with surgeons who 
care for more melanoma cases. 143,171 
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To increase compliance with melanoma surgical guidelines it has been 
recommended to develop metrics that record and monitor the following of 
melanoma surgical guidelines nationally. 170 Since patients are often referred to a 
melanoma specialist following treatment that did not follow the guidelines, Wasif 
et al recommended regionalization of melanoma treatment as is done for some 
other cancer types to increase compliance. 53,170 It could also be argued that 
although the guidelines are published and disseminated that there needs to be a 
concerted effort to better educate all clinicians especially those in Appalachia, 
counties with low all-physician density or high poverty. Additionally, clinicians 
need to be made aware of those patients that are at higher odds of receiving 
non-standard treatment. Lastly, patient education on melanoma treatment 
guidelines may empower patients in the physician-patient discussion of treatment 
options.  
There are limitations to this study that need to be considered when 
interpreting the findings. The primary limitation is the utilization of county level 
data for poverty and education that were used as surrogates for socioeconomic 
status. Although, the use of aggregate measures of socioeconomic status has 
been validated by other studies it still cannot replace individual level data. 29-31 
Although this study utilized cancer registry data that is regarded for its quality, it 
must be pointed out that the margins recorded are pathological and not clinical. It 
is known that there is shrinkage of the lesion, 10-20%, following histologic 
processing that would affect the recorded margin. 172 This study utilized surgery 
codes with no residual tumor as the definition of standard of care to avoid this 
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limitation but this effect is still possible. While this limitation is noted it would not 
account for this degree of noncompliance. 53 
Another limitation is the analysis of poverty level, education level and 
physician density by county in a state with 120 counties. This may have been too 
fine of a categorization of the data and further research should consider analysis 
by larger geographic regions. Lastly, this study was restricted to the state of 
Kentucky, which may not be representative of other parts of the country.  
While there is vast amounts of literature on other aspects of melanoma the 
literature on treatment adherence is limited. Further research should be guided 
by a need to better understand the variables pertaining to both the patient and 
physician in melanoma treatment decisions. Analysis of non-compliance by type 
of provider could lend insight into who is less likely to follow guidelines. 
Additionally, future research needs to evaluate the cost of under treatment and 
how to provide the highest quality of care to the largest number of melanoma 
patients.  
To determine the effect of non-adherence, further analysis is needed with 
long term follow up to evaluate for the effects of morbidity and mortality. For 
example, over the last few decades while the incidence of melanoma has 
increased in the US from 7.9 cases per 100,000 population in 1975 to 24.0 cases 
in 2013, the mortality rate for melanoma has remained steady at 2.7 deaths per 
100,000 population. 157 In Kentucky, the incidence of melanoma has also 
increased from 22.1 cases per 100,000 population in 1995 to 24.3 cases in 2013. 
However, the mortality rate has also increased from 2.5 cases per 100,000 
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population in 1994 to 3.4 cases in 2013. If the Kentucky mortality rates could be 
lowered to the national rates this would result in approximately 30 fewer 
melanoma deaths in Kentucky per year. 157 Therefore, further research should 
investigate the increasing non-compliance of surgical guidelines and the 
association with this high mortality rate.  
This analysis determined that 40% of early-stage melanoma lesions in 
Kentucky were provided non-standard treatment and that the rate of non-
standard surgical treatment is on the rise. This is a public health concern that 
needs intervention. Additionally, this study confirmed that those at increased odd 
of non-standard treatment live in Appalachia, a county with low all-physician 
density or a county with high poverty and high family practice physician density. 
The state of Kentucky needs to implement policy that increases patient access to 
melanoma care and educates clinicians to halt the trend of increasing non-
standard melanoma treatment.  
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Chapter V 
Conclusion 
 This capstone attempted to quantify the association of individual and 
social factors on melanoma late-stage diagnosis and non-adherence to surgical 
treatment guidelines in Kentucky. Figure 1.1, presented in Chapter 1, depicts the 
variables analyzed in this capstone that could affect both disease stage of 
diagnosis and surgical treatment provided. The purpose of this concluding 
chapter is to summarize the findings of the preceding chapters, discuss the 
implications of these studies for public health and to summarize the limitations 
and recommendations. This work was intended to identify future public health 
avenues to decrease late-stage diagnosis and non-adherence to melanoma 
surgical treatment guidelines.  
 
Summary of Findings  
In chapter 3, the first paper hypothesized that late-stage lesions occur 
more frequently in geographic areas with lower physician density and lower 
socioeconomic status (SES) as indicated by an increase in poverty level and 
decrease in education level. The analysis of melanoma lesions from 1995 to 
2013 did not show an association between these variables of interest. Rather, 
this study supports previous research that there is a decrease in odds of late-
stage diagnosis if female, married and carrying private insurance. 65,123,125 
In both papers, county poverty levels and county high school graduation 
levels were used as contextual variables to evaluate SES.  These variables have 
been validated to assess SES but are community level, not individual level data. 
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30,31 Since this analysis did not demonstrate an association between poverty or 
education at the county level, further research needs to be conducted with 
individual level data.  
In a state that has received recognition for the effective expansion of the 
Affordable Care Act the association between private health insurance and late-
stage diagnosis is intriguing. Further research needs to be conducted on the 
effect of providing insurance to over 500,000 uninsured Kentuckians and if 
decreases the rate of late-stage melanoma diagnosis. 162 
Kentucky is a rural state with high poverty, lower than average education 
levels and low physician density but it appears that these factors have not 
impacted melanoma stage of diagnosis.  As the rate of melanoma continues to 
increase, this paper finds that Kentucky needs to focus preventative health 
measures towards unmarried men who are uninsured or insured with Medicaid or 
Medicare. 
In chapter 4, the second paper hypothesized that non-standard treatment 
is associated with geographic region of both rural and Appalachia, decrease in 
physician density, increase in poverty level and decrease in education level. This 
analysis of early-stage melanoma lesions from 1995 to 2013 found that 40% of 
these cases were provided non-standard surgical treatment. Additionally, it was 
noted that the incidence of non-standard surgical treatment is actually increasing 
over time.  
This paper discovered an association between non-standard treatment 
and the variables of interest: Appalachian geography, poverty level and physician 
 92 
density. The effect of physician density is intriguing as low all-physician density 
increases the odds of non-standard therapy while low dermatologist density 
decreases the odds.  At the same time, in counties of high family practice 
physician density if the county also had a high poverty level there was a 
significant increase in non-standard treatment compared to low poverty counties. 
This analysis indicates increasing physician density in general improves 
adherence to melanoma surgical treatment guidelines but that increasing 
specifically family practice or dermatologist density does not.  
While physician and patient preference during treatment discussions is 
difficult to study this study lends some insight into which patients may be 
vulnerable. This includes patients older than 65 years with a head or neck lesion, 
and with unknown insurance status. Additionally, those residing in Appalachia, a 
county with low all-physician density or a county with high or intermediate poverty 
with high family practice density and high dermatologist density are susceptible. 
The specific needs of the patient have priority over general guidelines so 
compliance with melanoma surgical guidelines is not expected to be 100% but 
40% noncompliance is considered too high. Further research should be directed 
by a desire to improve the understanding of the factors that influence melanoma 
treatment decisions between the patient and physician. Policy implementation 
should focus on the need to increase patient access to melanoma care while 
educating clinicians to end the trend of increasing non-standard melanoma 
treatment in the state. Future research should also investigate the increasing 
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non-compliance of surgical guidelines and the possible association with the 
stable to slightly increasing mortality rate in Kentucky.  
The analyses from these two papers will be beneficial for public health 
practitioners because this is the first attempt to evaluate individual and social 
factors influencing disease stage and treatment of melanoma in Kentucky.  
 
Implications for Public Health 
 
The role of public health is to protect the health of the entire population 
through assessment, policy development and assurance. Therefore, the role of 
public health professionals is to assess which populations are vulnerable. 
Vulnerable populations are often defined by their social determinants of health in 
which the majority of a person’s health in the United States (US) is formed. The 
health of a population is generally recognized by the five determinants of health; 
biology and genetics, individual behavior, social environment, physical 
environment and health services. 173 
This capstone has attempted to define the vulnerable population by 
evaluating the effects of biology, social environment and health services on 
melanoma. The incidence of melanoma is increasing faster than any other 
preventable cancer in the US with an expected 112,000 new cases a year by 
2030. 2,3 Melanoma is a unique cancer because incidence occurs in a positive 
social gradient, where those with higher SES have the highest incidence while 
those with low SES have higher rates of late-stage disease and higher mortality 
rates. 6 
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This capstone reinforced previous papers that highlight the increased 
odds of late-stage melanoma in unmarried men who are uninsured or have 
Medicaid or Medicare. This draws attention to the complex interplay between 
gender, social support of marriage and access to health services. As public 
health professionals, our role is to direct our screening efforts toward unmarried 
men without private insurance. Additionally, we must push for policy changes that 
increase insurance coverage for this population.     
 Supporting preceding research, this capstone found that 40% of early-
stage melanoma lesions do not receive the standard of care surgical treatment 
and that the incidence of non-standard treatment is on the rise. 28,130,85142,143 This 
disparity in melanoma treatment is a public health concern. As epidemiologists, it 
is our role to bring to light the factors that are influencing a population’s health. 
The healthcare community needs to be made aware of this disparity and who is 
at highest risk for non-standard treatment.  We must determine why those who 
reside in Appalachia are twice as likely to receive non-standard surgical 
treatment. At the same time, public health leaders need to implement policy that 
increases patient access to melanoma care and educates clinicians to stop this 
trend within the state.  
 
Strengths and Limitations 
 
 This capstone has several strengths including that it is the first to evaluate 
individual and social factors influencing disease stage and treatment of 
melanoma in Kentucky. Also, due to the excellent cancer registry within the state, 
this capstone analyzed over 10,000 cases, which provided a robust sample size. 
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Another strength of this capstone is the novel methodology of evaluating surgical 
treatment adherence for early-stage disease that had not previously been 
evaluated in a mostly rural, impoverished and Appalachian population. While the 
literature on melanoma incidence and mortality is strong the information on 
treatment is anemic. This capstone hopes to add to this information gap.  
Despite these strengths, this capstone also has limitations, presented in 
chapters 3 and 4. In both papers the most notable limitation is the utilization of 
surrogates for SES. Although, the use of aggregate measures of SES has been 
validated by other studies it still cannot replace individual level data. 29-31 Also, 
the use of physician density was used in this study and can only be considered 
an aggregate of patients’ use of medical services. This data is cross sectional 
from 2006 and may not fully represent the small variations in the physician 
workforce from 1995 to 2013. The actual use of physician services by these 
patients may not be reflective of the physician density. Additionally, this analysis 
of physician density provides no insight into physician practice patterns or the 
utilization of non-physician clinicians including physician assistants and nurse 
practitioners.  
Another important limitation is that the analysis of poverty level, education 
level and physician density was done by county in a state with 120 counties and 
this may be a too fine a breakdown of the data. Future research may better 
capture community level characteristics with analysis of larger geographic 
regions. Lastly, this study was restricted to the state of Kentucky, which may not 
be representative of other parts of the country.  
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Recommendations 
 
 Future research is needed to help public health researchers to disentangle 
the complex relationship between individual and social factors in melanoma 
diagnosis and treatment. In addition to recommendations noted above, further 
research should be guided by a need to better understand the variables 
pertaining to both the patient and physician in melanoma treatment decisions. 
Researchers could gather more information regarding these treatment decisions 
through chart review or physician and patient survey.  
To improve the evaluation of physician density, it is recommended that 
future research also collect data on non-physician providers who directly 
diagnose and treat melanoma patients. Researchers may also be able to 
address the issue of access to care through the use of GIS mapping techniques.   
Over the last few decades the mortality rate for melanoma has not 
improved, remaining stable nationally and slightly increasing in Kentucky. 7 To 
date the association between clear margins and morality rate has not been 
confirmed. 54 Researchers should initiate a study with long term follow up to 
define the effect of non-adherence to treatment guidelines on morbidity and 
mortality.  
Lastly, in a country that has lost control of the cost of health care, future 
research needs to evaluate the cost of non-standard treatment and how to 
provide the highest quality of care to the largest number of melanoma patients. 
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Virginia L. Valentin 
 
University of Utah 
Department of Family and Preventive Medicine 
Physician Assistant Studies 
 
 
 
Date of birth: October 5, 1978 
Place of birth: Portsmouth, Virginia  
 
EDUCATION 
Years Degree Institution (Area of Study) 
1997 - 1999  R.N.  Weber State University  
Ogden, UT  
1998 - 2001  B.S.  University of Utah (Psychology)  
Salt Lake City, UT  
2004 - 2007  M.C.M.S.  Barry University (Physician Assistant Studies)  
Miami Shores, FL  
Masters in Clinical Medical Science and Physician Assistant 
Certification  
 
PROFESSIONAL EXPERIENCE  
1997 - 1999  Certified Nursing Assistant, Intermountain Health Care, Salt Lake 
City, UT  
 
1999 - 2000  Licensed Practical Nurse, Intermountain Health Care, Salt Lake City, 
UT  
 
2001 - 2002  Registered Nurse, LDS Hospital, Intermountain Health Care, Salt 
Lake City, UT  
 
2002  Registered Nurse, Willamette Valley Cancer Center, Eugene, OR  
 
2003 - 2005  Clinical Research Supervisor, Willamette Valley Cancer Center, 
Eugene, OR  
 
2008 - 2010  Physician Assistant, Neurosurgical Associates, Lexington, KY  
  
2010 - 2012  Physician Assistant, Markey Cancer Center, University of Kentucky, 
Lexington, KY  
 
2012 – 2016 
 
 
2016- current  
Assistant Professor, University of Kentucky College of Health 
Sciences, Lexington, KY 
 
Assistant Professor, Associate Director, University of Utah, Physician 
Assistant Studies, Salt Lake City, Utah 
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SCHOLASTIC HONORS 
2006  Outstanding PA student Scholarship, award recipient, awarded by 
faculty to overall best physician assistant student, Master of 
Physician Assistant Studies, Barry University, Miami, FL  
2007  Emanuel Fien Memorial Scholarship, award recipient, awarded for 
excellence in physical diagnosis, Master of Physician Assistant 
Studies, Barry University, Miami, FL  
2013  A Teacher Who Made a Difference, Student nominated University 
teaching award, University of Kentucky, Lexington, KY  
2016 - 2017  Breitman-Dorn Research Fellowship. Physician Assistant 
Foundation.  
 
ADMINISTRATIVE EXPERIENCE  
Professional Organization & Scientific Activities 
2006  Member, American Academy of Physician Assistants, Student 
Assembly of Representatives  
2007  Member, American Academy of Physician Assistants, Student 
Assembly of Representatives  
2010 - 2012  Representative, Kentucky Academy of Physician Assistants, Central 
Region Representative 
• Developed and implemented monthly CME dinners  
2010 - Present  Member, Kentucky Academy of Physician Assistants, Legislative 
Committee  
2012 - 2014  Member, Kentucky Academy of Physician Assistants, Annual CME 
Committee  
2012  Member, American Academy of Physician Assistants, House of 
Delegates for Kentucky, Toronto  
2012 - 2013  President-Elect, Kentucky Academy of Physician Assistants,  
• Passed state legislation to eliminate 18 month supervision 
• Invested in new lobbying team  
2013  Member, American Academy of Physician Assistants, House of 
Delegates for Kentucky  
2013 - 2014  President, Kentucky Academy of Physician Assistants,  
• Passed state legislation to decrease co-signatures to 10% 
• Increased board and membership involvement 
• Began PA week statewide celebrations  
2014 - Present  Member, Physician Assistant Education Association, Government 
Relations and External Affairs Council (GREAC)  
2014 - 2015  Past President, Kentucky Academy of Physician Assistants,  
• Proposed state legislation to increase PA:MD ratio to 4:1 
• Invested in larger management association  
2015  Member, American Academy of Physician Assistants, House of 
Delegates for Kentucky  
 
Symposium/Meeting Chair/Coordinator 
2013  Organizer & Participant, Kentucky Academy of Physician Assistants 
Annual Conference, Lexington, KY  
2014  Organizer & Participant, Kentucky Academy of Physician Assistants 
Annual Conference, Lexington, KY  
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PROFESSIONAL COMMUNITY ACTIVITIES 
2002 - 2005  Registered Nurse Volunteer, Volunteers in Medicine Clinic, Volunteer 
Run Primary Care Clinic, Eugene, OR 
• Performed nursing duties and operated as pharmacy leader  
2003  Registered Nurse Volunteer, Cascade Health Solutions, Medical 
Mission to Guatemala (2 weeks) 
• Performed nursing duties at inpatient hospital  
2005  Registered Nurse Volunteer, Cascade Health Solutions, Medical 
Mission to Guatemala (2 weeks) 
• Performed nursing duties at inpatient hospital  
2011 - Present  Program Coordinator, Blessings in a Backpack, Lexington, KY 
• Organized volunteers, coordinated monthly food shipments and 
weekly delivers to elementary school students 
• Provides food to 60 children each week to supplement nutrition for 
the weekend  
2012  Interviewee, Louisville Business First, Interviewed and quoted for 
article regarding increasing role of Physician Assistants in health 
care in Kentucky  
2012 - 2013  Physician Assistant, Kentucky Bone and Joint Surgeons,  
• Clinical work one day a week as a PA in orthopedic clinic  
2013  Interviewee, WEKU Radio, Kentucky, interviewed as the President-
elect of Kentucky Academy of Physician Assistants  
2013  Interviewee, Jessamine Journal, Interviewed and quoted for article 
regarding Senator Buford's award as legislator of the year  
2014  Interviewee, Kentucky Radio Stations, Radio interview regarding 
2014 PA legislation, played on 114 radio stations in Kentucky  
 
SERVICE AT PREVIOUS INSTITUTIONS 
2011 - Present  Member, University of Kentucky, Advanced Practice Providers  
2012 - 2015  Academic Advisor, University of Kentucky,  
• Advised students throughout their PA education 
• Monitored academic advancement through lock step curriculum and 
met with students throughout their 28 month program to discuss their 
progress.  
2012  Faculty Representative, University of Kentucky College of Health 
Sciences, Physician Assistant Studies 
• Developed and implemented shadowing program for 60 PA 
students as two campuses  
2012 - 2014  Faculty Advisor, University of Kentucky, Physician Assistant 
Program, Joseph Hamburg Student Society Class of 2014 
• Advising position elected by PA student 
• Advised/attended each monthly student board meeting 
• Raised $2,000 for New Hope free clinic  
2012 - Present  Member, University of Kentucky College of Health Sciences, 
Physician Assistant Studies, Admissions Committee 
• Developed and implemented holistic admissions with goal of 
increasing diversity  
2012 - Present  Member, University of Kentucky College of Health Sciences, 
Physician Assistant Studies, Clinical Curriculum Committee  
2012 - Present  Member, University of Kentucky College of Health Sciences, 
Physician Assistant Studies, Didactic Curriculum Committee  
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2012 - Present  Member, University of Kentucky College of Health Sciences, 
Physician Assistant Studies, Curriculum Development Committee 
• Analysis of current curriculum and development of new curriculum 
proposal  
2012  Faculty Mentor, University of Kentucky College of Health Sciences, 
AHEC interdisciplinary event to educate high school students about 
roles in health care  
2012  Group Facilitator, University of Kentucky College of Health Sciences, 
Common Reading Experience 
• Read and discussed Common Reading book with interdisciplinary 
students  
2012 - Present  Faculty Mentor, University of Kentucky College of Health Sciences,  
• PA mentor to pre-PA students 
• Individually student meetings to discuss PA profession 
• Formal presentation at pre-PA club meetings  
2012  Faculty Representative, University of Kentucky College of Health 
Sciences, Physician Assistant Studies 
• Developed and implemented a one-day student education track at 
the KAPA conference for PA students throughout the state each 
noted year 
• Hosted the 1st, 2nd, and 3rd annual KAPA Challenge Bowl  
2013  Faculty Representative, University of Kentucky College of Health 
Sciences, Physician Assistant Studies 
• Arranged PA students to participate in PA lobbying day at capitol in 
Frankfort, KY  
2013  Faculty Representative, University of Kentucky College of Health 
Sciences, Physician Assistant Studies 
• Developed and implemented shadowing program for 60 PA 
students as two campuses  
2013 - Present  Faculty Council Member, University of Kentucky College of Health 
Sciences  
2013  Faculty Representative, University of Kentucky College of Health 
Sciences, Physician Assistant Studies 
• Developed and implemented a one-day student education track at 
the KAPA conference for PA students throughout the state each 
noted year 
• Hosted the 1st, 2nd, and 3rd annual KAPA Challenge Bowl  
2014  Faculty Representative, University of Kentucky College of Health 
Sciences, Physician Assistant Studies 
• Arranged PA students to participate in PA lobbying day at capitol in 
Frankfort, KY  
2014  Faculty Representative, University of Kentucky College of Health 
Sciences, Physician Assistant Studies 
• Developed and implemented a one-day student education track at 
the KAPA conference for PA students throughout the state each 
noted year 
• Hosted the 1st, 2nd, and 3rd annual KAPA Challenge Bowl  
2014 - Present  Physician Assistant, University of Kentucky Medical Center, Clinical 
work one day a week as internal medicine hospitalist PA  
2015  Faculty Representative, University of Kentucky College of Health 
Sciences, Physician Assistant Studies 
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• Arranged PA students to participate in PA lobbying day at capitol in 
Frankfort, KY  
 
MEMBERSHIPS IN PROFESSIONAL SOCIETIES 
2005 - Present  Member, American Academy of Physician Assistants  
2008 - Present  Member, Kentucky Academy of Physician Assistants  
2012 - Present 
2016 - Present  
Member, Physician Assistant Education Association 
Member, Utah Academy of Physician Assistants  
 
FUNDING  
09/01/13 - 
12/31/14  
OHNEP: Integrating Oral Health with Primary Care: Engaging 
Students in Advanced Nursing Practice and Physician Assistant 
Studies  
Principal Investigator: K Skaff  
Direct Costs: $2,000    Total Costs: $2,000  
Oral Health Nursing Education & Practice  
Role: Co-Instructor  
 
TEACHING RESPONSIBILITIES/ASSIGNMENTS  
Courses Directed 
2012 - 2013  Course Director, PAS 669 Internal Medicine Clerkship, Physician 
Assistant Studies, University of Kentucky 
• 6 credit course, yearlong course, distance learning, 60 students 
• Each student takes course for 8 weeks working in internal medicine 
gaining experience in both ambulatory and hospital settings  
Fall 2012  Course Director, PAS 650 Clinical Methods, Physician Assistant 
Studies, University of Kentucky 
• 4 credit course, 60 students on two campuses 
• 3 hour lab session, three times a week 
• This course is designed to teach students to perform and document 
a complete history and physical exam  
2013 - 2014  Course Director, PAS 663 Surgery Clerkship, Physician Assistant 
Studies, University of Kentucky 
• 3 credit course, yearlong course, distance learning, 60 students 
• Each student takes course for 4 weeks working in surgical setting  
Fall 2013  Course Director, PAS 650 Clinical Methods, Physician Assistant 
Studies, University of Kentucky 
• 4 credit course, 60 students on two campuses 
• 3 hour lab session, three times a week 
• This course is designed to teach students to perform and document 
a complete history and physical exam  
Spring 2014  Course Director, PAS 651 Introduction to the PA Profession, 
Physician Assistant Studies, University of Kentucky 
• 2 credit course, 60 students on two campuses 
• This course is designed to cover health care issues for the primary 
care physician assistant and is taught in module format: PA 
profession for 10 weeks and ethics for 5 weeks which is taught by a 
co-instructor  
2014 - 2015  Course Director, PAS 669 Internal Medicine Clerkship, Physician 
Assistant Studies, University of Kentucky 
• 6 credit course, yearlong course, distance learning, 60 students 
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• Each student takes course for 8 weeks working in internal medicine 
gaining experience in both ambulatory and hospital settings  
Fall 2014  Course Director, PAS 650 Clinical Methods, Physician Assistant 
Studies, University of Kentucky 
• 4 credit course, 60 students on two campuses 
• 3 hour lab session, three times a week 
• This course is designed to teach students to perform and document 
a complete history and physical exam  
Spring 2015  Course Director, PAS 651, Introduction to the PA Profession, 
Physician Assistant Studies, University of Kentucky 
 
Summer 2016  FPMD 6040 Introduction to Professional Issues, Physician Assistant 
Studies, 48 students  
Summer 2016  FPMD 6023 Oncology Course, Physician Assistant Studies, 45 
students  
Fall 2016  FPMD 6041 Professional Issues and Cultural Competency, Physician 
Assistant Studies, 46 students  
Fall 2016  FPMD 6051 Evidence Based Medicine Course, Physician Assistant 
Studies, 46 students  
Fall 2016  FPMD 6011 Hematology Course, Physician Assistant Studies, 45 
students  
 
Course Lectures 
Nov 2011  Guest Lecturer, PAS 654: Clinical Lecture Series I, University of 
Kentucky. Physician Assistant Program, Lymphoma and Multiple 
Myeloma  
Apr 2012  Guest Lecturer, PAS 654: Clinical Lecture Series I, University of 
Kentucky, Physician Assistant Program. Lymphoma and Multiple 
Myeloma 
July 2012  Guest Lecturer, PAS 654: Clinical Lecture Series I, University of 
Kentucky, Physician Assistant Program. Anemia, Clotting and 
Bleeding disorders 
Sept 2012  Guest Lecturer, PAS 657: Clinical Lab Procedures, University of 
Kentucky, Physician Assistant Program. Assessment of Hemostasis 
Nov 2012  Guest Lecturer, PAS 654: Clinical Lecture Series I, University of 
Kentucky, Physician Assistant Program. Lymphoma and Multiple 
Myeloma 
Dec 2012  Guest Lecturer, MLS 460: Clinical Hematology, University of 
Kentucky, Medical Laboratory Science Program. Treatment of 
Leukocyte Disorders 
Spring 2013  Co-Instructor, PAS 656: Patient Evaluation and Management, 
University of Kentucky, Physician Assistant Studies.  
• 4 credit course, 60 students on two campuses 
• 3 hour lab session, meets three times a week 
• Course is taught in a block format with ECG, radiology and 
procedures  
Mar 2013  Guest Lecturer, PAS 651: Introduction to the PA Profession, 
University of Kentucky, Physician Assistant Studies. PA Advocacy 
Mar 2013  Guest Lecturer, PAS 651: Introduction to the PA Profession, 
University of Kentucky, Physician Assistant Program. Health Care 
Inequalities  
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Sept 2013  Guest Lecturer, PAS 654: Clinical Lecture Series I, University of 
Kentucky, Physician Assistant Program. Anemia, Clotting and 
Bleeding disorders 
Dec 2013  Guest Lecturer, MLS 460: Clinical Hematology, University of 
Kentucky, Medical Laboratory Science Program. Treatment of 
Leukocyte Disorders  
Sept 2014  Guest Lecturer, PAS 654: Clinical Lecture Series I, University of 
Kentucky, Physician Assistant Program. Lymphoma and Multiple 
Myeloma 
Sept 2014  Guest Lecturer, PAS 654: Clinical Lecture Series I, University of 
Kentucky, Physician Assistant Program. Anemia, Clotting and 
Bleeding disorders  
Dec 2014  Guest Lecturer, MLS 460, University of Kentucky, Clinical 
Hematology, Medical Laboratory Science Program. Treatment of 
Leukocyte Disorders  
Spring 2015  Co-Instructor, PAS 656: Patient Evaluation and Management, 
University of Kentucky, Physician Assistant Studies.  
• 4 credit course, 60 students on two campuses 
• 3 hour lab session, meets three times a week 
• Course is taught in a block format with ECG, radiology and 
procedures  
Spring 2016  Instructor, University of Utah. FPMD 6042 Tutorial Course, Small 
Group Teaching, Physician Assistant Studies, 4 students  
Summer 2016  Instructor, University of Utah. FPMD 6043 Tutorial Course, Small 
Group Teaching, Physician Assistant Studies, 4 students  
Fall 2016  Instructor, University of Utah. FPMD 6041 Tutorial Course, Small 
Group Teaching, Physician Assistant Studies, 4 students  
 
Small Group Teaching 
May 2012  Small Group Facilitator, PAS 610 Research Methods, Physician 
Assistant Program, University of Kentucky  
May 2012  Small Group Facilitator, CNU 503 Applied Nutrition, Physician 
Assistant Program, University of Kentucky  
June 2014 - 
Present  
Small Group Facilitator, iCats Year 1, Inter-professional education 
program, University of Kentucky 
• Member of IPE program development 
• 2 year curriculum of IPE education including PA, PT, RN and 
PharmD students  
 
Trainee Supervision 
Masters  
2013 - 2014  Research Supervisor, Brittany Cianelli, Physician Assistant Program, 
University of Kentucky. Pain Crisis of Pediatric Sickle Cell Patients 
Adversely Affects Quality of Life  
 
Educational Lectures  
Department/Division Conferences 
2013  PA Advocacy, PA Program Orientation, Physician Assistant Program, 
University of Kentucky  
2013  Physician Assistants Legislation Update, University of Kentucky 
Advanced Practice Providers Quarterly Meeting  
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2013  PA Advocacy, PA Program Orientation, Physician Assistant Program, 
University of Kentucky  
2013  Kentucky Physician Assistants in the future health care system, 
Allied Health Week, University of Kentucky College of Health 
Sciences  
2014  Physician Assistants Legislation Update, University of Kentucky 
Advanced Practice Providers Quarterly Meeting  
2014  PA Advocacy, PA Program Orientation, Physician Assistant Program, 
University of Kentucky  
 
Continuing Education  
CE Courses Taught 
2016  Faculty Skills 101 PANDO Workshop, Physician Assistant Educators, 
30 participants, 15 hours CME  
 
PEER-REVIEWED JOURNAL ARTICLES 
 
1. Coombs J, Valentin VL (2014). Salary Differences of Male and Female PA 
Educators. Journal of Physician Assistant Education. 
2. Valentin VL, Dehn RW, Baker MD (2016). Commentaries on health services 
research. JAAPA, 29(2), 1-2. 
3. Morgan P, Everett CM, Humeniuk KM, Valentin VL (2016). Physician assistant 
specialty choice: Distribution, salaries, and comparison with physicians. JAAPA, 
29(7), 46-52. 
 
Other (Commentary/Letters/Editorials/Case Reports/Video/Film)  
 
1. Valentin VL (2014). Changes in PA Certification Maintenance. Kentucky Academy of 
Physician Assistants newsletter. 
2. Valentin VL (2014). Physician Assistant students participating in PA legislation day 
at the state capital. Connection Magazine. 
3. Valentin VL (2014). Can PAs call Kentucky home? Medical News (22(2), p. 22). 
4. Valentin, V, Young, A, Lasley-Bibbs, V (2015). 2015 Kentucky Minority Health Status 
Report. Kentucky Department of Public Health. 
 
Video/Film/CD/Web/Podcast 
1. Valentin VL (2013). State presidential appointment [Web]. University of Kentucky 
web publication. Available: uknow.uky.edu. 
2. Valentin VL (2013). President Message [Web]. Kentucky Academy of Physician 
Assistant website. Available: http://kentuckypa.org/. 
 
ORAL PRESENTATIONS  
Meeting Presentations (Not Published Abstracts and Not Unpublished Posters) 
International 
2014  Taylor S, Jones M, Schuer KM, Bennett TL, Valentin VL, Jones M. 
Faculty Development in Inter-professional Education. US-Thai 
Consortium for the Development of Pharmacy Education, Thailand  
National  2013  Coombs J, Valentin VL. Is There A Glass Ceiling Over Female 
Physician Assistant Educators? American Academy of Physician 
Assistants Annual Conference, Washington, DC  
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2013  Skaff KO, Valentin VL. Preparing Faculty to Teach the Oral Cancer 
Screen. Physician Assistant Education Association Annual Education 
Forum, Workshop, Memphis, TN  
2013  Coombs J, Valentin VL. Is There A Glass Ceiling Over Female 
Physician Assistant Educators? Physician Assistant Education 
Association Annual Education Forum, Memphis, TN  
2014  Valentin VL, Bennett TL, Jones J, Hooker R. The Kentucky 
Physician Assistant Workforce: 2013. American Academy of 
Physician Assistants Annual Conference, Boston, MA  
2014  Valentin VL, Bennett TL, Jones J, Hooker R. The Kentucky 
Physician Assistant Workforce: 2013. Physician Assistant Education 
Association Annual Conference, Philadelphia, PA  
2015  White, R, Allman, M, Mealy, K, Valentin, VL, DeRosa, M, Horvath, T. 
Fellow Advocacy Session. Physician Assistant Education Association 
Annual Conference, Washington, DC.  
2016  Valentin, VL, Coombs, J, Jones, J. Where are all the Physician 
Assistants in the Beehive State? Physician Assistant Education 
Association Annual Conference, Minneapolis, MN.  
2016  White, R, Allman, M, Mealy, K, Valentin, VL, DeRosa, M, Horvath, T. 
Fellow Advocacy Session. Physician Assistant Education Association 
Annual Conference, Minneapolis, MN.  
Local/Regional  2012  Valentin VL, Powdrill SG. Suturing workshop for Practicing PAs. 
Workshop, Kentucky Academy of Physician Assistants 36th Annual 
Symposium, Lexington, KY  
2013  Valentin VL. Anemia, A Review of Anemia for the PANCE/PANRE 
exam. Kentucky Academy of Physician Assistants 37th Annual 
Symposium, Lexington, KY  
2013  Valentin VL. Patient Center Medical Home-Collaborating Physician 
Training Panel. Kentucky Academy of Family Physicians & 
Foundation Annual Meeting, Lexington, KY  
2014  Valentin VL, Bennett TL, Jones J, Hooker R. The Kentucky 
Physician Assistant Workforce: 2013. Public Health Services and 
Systems Research Keeneland Conference, Lexington, KY  
2014  Valentin VL. Webinar Category 1 CME: Physician Assistants-What 
you need to know about the profession and how the new law will 
impact their practice. Kentucky Academy of Family Physicians, 
Lexington, KY  
2014  Coombs J, Valentin VL. Is There A Glass Ceiling Over Female 
Physician Assistant Educators? Women's Health Sex and Gender 
Research Conference Info Fair, Salt Lake City, Utah, UT  
2014  Valentin VL, Bennett TL, Jones J, Hooker R. The Kentucky 
Physician Assistant Workforce: 2013. Kentucky Rural Health 
Association Annual Conference, Bowling Green, KY  
 
Peer-Reviewed Presentations 
National 
2016  Christian, J, Chauhan, A, Anthony, L, Nee, J, Huang, B, Durbin, E, 
Stewart, R, Valentin, V, Absher, K, Vanderford, N, Arnold, S. Spatio-
temporal Analysis of Large Cell Neuroendocrine Lung Cancer in 
Kentucky, 1995-2012. Geospatial Approaches to Cancer Control and 
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Population Sciences. Bethesda, MD.  
 
OTHER SCHOLARLY ACTIVITY  
 
2015  Chair Academy, participant, University of Kentucky 
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